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Abstract 
 
The medicinal uses of gold date as far back as 2500 B.C. in China. In modern times, gold has 
been used in the treatment of a number of different human diseases including rheumatoid arthritis, 
cancer, and viral infections. This dissertation will focus on the development of gold complexes for 
the purpose of selective inhibition of HIV NCp7, a 55 amino acid zinc finger protein with two 
Cys3His zinc binding domains. 
NCp7 is involved in a number of viral life cycle processes including activation of reverse 
transcription, integration, DNA recognition, RNA packaging, and formation of the viral envelope. 
The diversity in the roles of NCp7 across the viral life cycle make it a highly attractive target for 
chemical intervention. Ejection of the tetrahedrally coordinated zinc atoms, modification or 
deletion of the zinc coordinating amino acids, or modification or deletion of the “essential” 
tryptophan residue can result in the loss of viral infectivity. This is due to the inability of NCp7 to 
recognize its “natural” substrate – polynucleic acids. Previous studies have investigated the 
differences in the manner in which platinum(II), gold(I), and gold(III) complexes interact with 
xx 
 
NCp7. The platinum(II) complex [Pt(dien)(9-EtGua)]2+ interacts with the C-terminal zinc finger 
of NCp7 in a non-covalent manner, through a π-π stacking interaction between the platinated 9-
EtGua and the “essential” tryptophan residue. The isostructural and isoelectronic complex 
[Au(dien)(9-EtGua)]3+ ejects the tetrahedrally coordinated zinc atom and replaces it with a gold 
atom, forming “gold fingers”. This result is consistent with the interactions of the gold(I) complex 
[(PPh3)Au(9-EtGua)]
+. 
In order to complete the series of isoelectronic and isostructural platinum(II), palladium(II), 
and gold(III) complexes with N-heterocyclic ligands and diethylenetriamine chelates, the 
complexes [Au(dien)(1-MeCyt)]3+ and [Au(N-Medien)(1-MeCyt)]3+ were synthesized. These 
complexes were found to dimerize the C-terminal zinc finger once the central zinc atom is ejected. 
This is likely the result of a charge transfer from the 1-methylcytosine ligand to the tryptophan 
residue, and is a product that was not seen as a result of interaction with the previously published 
4-dimethylaminopyridine and 9-ethylguanine analogs. The 1-methylcytosine complexes also 
stabilize the gold(III) oxidation state and associate with N-acetyltryptophan in a manner consistent 
with the previously studied gold(III) analogs. Finally, in order to address concerns arising from 
the inner filter effect, a proof of concept study using 1H-NMR spectroscopy was utilized to show 
that the complex [Au(dien)(1-MeCyt)]3+ likely has a lower association constant with N-
acetyltryptophan than the value determined by fluorescence quenching. 
The impact of the incorporation of additional steric hindrance on the gold(III) chelate was 
studied using the di-(2-picolyl)amine ligand. The gold(III) chlorides incorporating this ligand and 
the centrally methylated analog were found to eject zinc from the C-terminal zinc finger of NCp7, 
and the electronegativity differences between the gold(III) and platinum(II) metal centers were 
xxi 
 
highlighted. The attempts to incorporate an N-heterocyclic ligand into these complexes were 
unsuccessful due to the steric and electronic demands of the chelate. 
The use of an organometallic chelating ligand led to the investigation of the ability of gold(III) 
complexes to catalyze the arylation of zinc-coordinating cysteine residues. The complex 
[AuCl2(dampa)], which had been formerly investigated as a chemotherapeutic agent due to its 
structural similarities to cisplatin, was found to arylate N-acetylcysteine, glutathione, and NCp7. 
The arylation was not found to be dependent on the cis- chloride ligand, as blocking that site with 
the ligand triphenylphosphine did not prevent the arylation of NCp7. The X-Ray crystal structure 
of the complex [AuCl(dampa)(PPh3)](PF6) was also solved. Using the advancement of the 
knowledge of how the electronic and structural properties of gold(III) complexes described herein 
impact interactions with NCp7, it is possible that a coordination complex that is a selective 
inhibitor of NCp7 may eventually be developed. 
  
1 
 
Chapter 1: Introduction 
 
1.1 Medicinal Uses of Gold Complexes 
The earliest known use of gold in a medicinal capacity dates back as far as 2500 B.C. in China, 
where gold was ingested in order to promote longevity and to cure a number of ailments such as 
fainting and delirium.1,2 These treatments generally took the form of ingestion of elemental gold, 
although the modern scientific community has been unable to confirm a medicinal value for this 
type of treatment.3 Modern chemical development of gold-based medicine began in earnest with 
the discovery that gold-cyanide inhibits the growth of Tubercule bacillus, which occurred in 
1890.1,2 This discovery led to the development of gold complexes with the hope of treating 
tuberculosis.3 Despite poor results in the treatment of tuberculosis in animal models, researchers 
ignored these findings and carried out human trials of gold based tuberculosis treatments.4 While 
these trials proved to be unsuccessful in preventing the progression of tuberculosis, trial 
participants noticed an improvement in joint pain, leading to the development of gold complexes 
for the treatment of rheumatoid arthritis.2,3 Two of the complexes developed for the treatment of 
rheumatoid arthritis during this time, aurothiomalate and aurothioglucose (Figure 1.1), are still in 
use in the clinic.2,3 In addition to clinical use for the treatment of rheumatoid arthritis, 
aurothiomalate and aurothioglucose are still being investigated for new applications as medicinal 
treatments. For example, aurothioglucose is being investigated as an inhibitor of thioredoxin 
reductase (TrxR), and aurothiomalate is being investigated as an inhibitor of zinc finger proteins.5–
7 The development of auranofin (Figure 1.1) in the 1970s was a significant advancement in the 
timeline of gold-based medicine, as it was the first orally active gold complex to be introduced 
into the clinic.8 While auranofin is clinically approved for the treatment of rheumatoid arthritis, it 
2 
 
continues to be investigated for a wide range of clinical applications including inhibition of TrxR, 
inhibition of angiogenesis, and antiviral applications.9–11 
  
Figure 1.1. The structure of sodium aurothiomalate (left), aurothioglucose (middle), and 
Auranofin (right). 
 
The widespread clinical acceptance of these gold-based rheumatoid arthritis treatments, and 
the discovery that auranofin was capable of inhibiting tumor cell growth both in vitro and in vivo, 
led to the development of a number of gold complexes for investigation of their potential as 
pharmaceuticals.2 In general, some trends in the development of these complexes can be observed, 
leading most of the complexes developed to fall into two classes: analogs of the antiarthritic agents, 
which are generally Au(I) complexes, and analogs of cisplatin, which make use of the isoelectronic 
nature of the Pt(II) and Au(III) oxidation states.2,3,12 
Many of the Au(I) complexes that have been developed were synthesized with the goal of 
inhibiting tumor growth contain a gold-sulfur bond and act as inhibitors of TrxR. Many, like 
auranofin, also contained phosphine ligands.2,12,13 One such example is Au-napth-1, which is an 
auranofin analog containing a napthalimide ligand in place of the carbohydrate ligand. This ligand 
was chosen because of the anticancer properties shown by other complexes containing 
napthalimide, and likely also targets TrxR.12 More recently, the design of Au(I) complexes has 
taken the complexes farther from direct analogs of auranofin. A wide variety of Au(I) complexes 
containing N-heterocyclic carbene (NHC) ligands, cyclodiphosphazene ligands, phosphole 
ligands, and cyclic thiourea ligands have been developed and examined for their ability to prevent 
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tumor growth and proliferation, largely through the targeting of TrxR or glutathione reductase 
(GR), which causes the generation of reactive oxygen species (ROS).2,12–14 The use of NHC as a 
ligand was inspired by the similarities in the donor properties of NHCs and phosphines and by the 
ease with which NHCs can be modified in order to tune the lipophilic properties of the complex.15 
The ease of modification of NHCs was also leveraged in the creation of [Au(NHCNap)Cl], which 
contains a naphthalene ligand capable of intercalating DNA, creating a synergistic reaction 
mechanism.14  
 
Figure 1.2. Mechanism of inhibition of Thioredoxin or Thioredoxin reductase by a gold 
complex.2 
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The phosphine ligand in auranofin was, at least at one time, considered critical to its function2. 
This led to the development of Au(I) complexes with multiple phosphine ligands. Two such 
complexes are [Au(dppe)2]
+ and [Au(dnpype)2]
+, which are both tetracoordinate Au(I) complexes. 
[Au(dppe)2]
+ was developed with the hope that the AuP4 coordination sphere would display 
reduced reactivity towards thiol containing biomolecules.2,16 Additionally, the AuP4 coordination 
sphere was found in [Au(dppe)2]
+ was found to have increased stability relative to the two-
coordinate Au(I) complexes that had been previously investigated.14 This complex showed 
stability in the presence of high concentrations of glutathione (GSH) and in vivo antitumor activity 
in animal models, but research on the complex as a chemotherapeutic agent was discontinued due 
to high toxicity, which was thought to be caused by general membrane permeability caused by 
accumulation of the complex in mitochondria.2,12,14,16 In order to reduce this toxicity, complexes 
analogous to [Au(dnpype)2]
+ were developed, which showed increased efficacy as a TrxR inhibitor 
and decreased toxicity towards healthy cells.2,12,14,17 Other analogs of [Au(dppe)2]
+ were designed, 
including [Au(dppp)(PPh3)Cl], [Au(P(CH2OH)3)4]
+, and the dinuclear complex 
[{AuCl(PPh3)}2(µ2-DIPHOS)], both of which showed antitumor activity to some extent, including 
[Au(P(CH2OH)3)4]
+, which advanced to clinical trials.2 
Despite the breadth of research that resulted from the discovery that auranofin and its analogs 
were active as antitumor agents, the most commonly used inorganic anticancer agents in the clinic 
continue to be cisplatin and cisplatin analogs such as carboplatin and oxaliplatin.18,19 While 
development of platinum based chemotherapies continues, the isoelectronic and isostructural 
relationship between Pt(II) and Au(III) has led to the investigation of Au(III) complexes as 
antitumor agents.2,12,14,20  One of the first such complexes was [AuCl2(dampa)] (dampa = N,N-
dimethylbenzylamine), which, like cisplatin, contains two cis chloride ligands.21 Further 
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experimentation led to the development of the complexes [Au(acetato)2(dampa)] and 
[Au(malonato)(dampa)], both of which showed in vivo tumor activity.22 
 
Figure 1. 3. The structures of some gold(III) complexes investigated as anti-cancer 
compounds.14 
 
Only three other types of gold complexes have been reported to show in vivo tumor activity: 
the Au(III) dithiocarbamate complexes such as [Au(DMDT)X2] and [Au(ESDT)X2](DMDT = 
N,N-dimethylthiocarbamate, ESDT = ethylsarcosinedithiocarbamate, X = Cl, Br), the Au(III) 
porphyrins such as [Au(III)(TPP)]+, and the Au(III) NHC complex [Au(C^N^C)(NHC)]+ (C^N^C 
= 2,6-diphenylpyridine).2,12,14 Analysis of a number of dithiocarbamate complexes revealed that 
the previously mentioned complexes [Au(DMDT)X2] and [Au(ESDT)X2] were the most effective 
complexes in the series, and were more cytotoxic than cisplatin in both sensitive and resistant cell 
lines. Activity in cell lines both sensitive and resistant towards cisplatin also proves a unique 
mechanism of antitumor activity relative to cisplatin.23 A number of mono-, di-, and even trinuclear 
complexes containing the tridentate chelating ligand 2,6-diphenylpyridine were also tested for 
their efficacy as chemotherapeutic agents. These complexes were rationally designed due to the 
6 
 
structural similarity they share with the metallointercalator [Pt(terpy)Cl]+, and the ligands that 
were investigated included N-donors, phosphines, and bridging phosphines. While the complexes 
did not exhibit remarkably high cytotoxicity, the phosphine ligands improved solubility, and it was 
concluded that their use could serve as a vehicle for the delivery of a cytotoxic analog.24 The 
moderate success of these complexes as cytotoxic agents led to the development of the mono- and 
polynuclear NHC analogs. These complexes were found to poison Topoisomerase I by stabilizing 
the enzyme-DNA complex, resulting in the lead compound, [Au(C^N^C)(NHC)]+, displaying a 
cytotoxic profile up to 28 times more effective than cisplatin.25 The complex is also significantly 
more effective than cisplatin against cisplatin resistant cell lines, which shows the difference in 
mechanism of action from cisplatin, which targets DNA forming crosslinks preventing normal 
DNA transcription and replication.26 Finally, porphyrin containing complexes such as [Au(TPP)]+ 
were synthesized in order to improve the stability of the Au(III) oxidation state in the presence of 
biologically relevant reducing agents such as glutathione.2,12,14 The meso-tetraarylporphyrin 
complexes investigated exhibited both stability towards reduction and significant cytotoxicity 
towards both cisplatin sensitive and resistant cell lines through dose-dependent induction of 
apoptosis as determined by confocal microscopy and flow cytometry.27 
Additional investigation of Au(III) complexes as isoelectronic and isostructural analogs of 
cisplatin were developed in the form of Au(III) complexes with one or more Au-N bonds.12,14,28 
Generally, these complexes contain a multidentate N-donor chelating ligand, and the structures of 
the chelating ligands that have been investigated are diverse. One of the most important 
developments from the research into the multidentate N-donor ligands is the stabilization of the 
Au(III) oxidation state under physiological (reducing) conditions that was observed for complexes 
such as [Au(phen)Cl2]
+, [Au(terpy)Cl]2+, [AuCl(dien)]2+, [Au(cyclam)]3+, and [Au(en)2]
2+ (phen = 
7 
 
phenanthroline, terpy = 2,2’:6’,2’’-Terpyridine, dien = diethylenetriamine, cyclam = 1,4,8,11-
tetraazacyclotetradecane, en = ethylenediamine).12 The cytotoxicities of these complexes were 
found to be comparable across cisplatin resistant and sensitive cell lines, and it was found by 
circular dichroism and DNA melting point assays that the dien and the phen complexes caused 
direct DNA damage.29  
 
Figure 1.4. The structure of gold(III) complexes investigated for their ability to cause direct 
DNA damage.29 
 
In addition to the uses of gold complexes as treatments for rheumatoid arthritis, as in the case 
of auranofin and its analogs, and as chemotherapeutic agents, such as the complexes that arose 
from the investigation of Au(III) analogs of cisplatin, gold complexes have been investigated as 
potential treatments for parasitic diseases and HIV/AIDS.2 The parasitic diseases for which gold 
complexes have been investigated as potential treatments include malaria, leishmaniasis, 
trypanomiasis, and schitsomiasis.30 
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Traditionally, chloroquine has been used to treat malaria, but the rise of chloroquine resistant 
parasites has necessitated development of new treatments.31 The parasite that causes malaria in 
humans, Plasmodium falciparum, possesses a thioredoxin reductase enzyme that have been 
identified as a target for antimalarial intervention.32 Initial studies of gold complexes as 
antimalarial agents used auranofin to target this enzyme. The other gold complexes investigated 
alongside auranofin were [Au(PEt3)Cl], aurothiomalate, and [Au(Cyclam)]
3+. Auranofin was the 
most successful complex of the four, and the ability of auranofin to inhibit P. falciparum growth 
in vitro was used to illustrate the efficacy of gold complexes as antiparasitic agents and show that 
further investigation was warranted.33 One of the most successful gold-based complexes 
investigated as an antimalarial agent was [Au(PPh3)(CQ)]
1+, which was developed to study the 
effect of modulating the electronic properties of chloroquine by binding it to gold as a ligand. 
Binding chloroquine to gold was a successful strategy, as the complex showed a significant 
enhancement of activity against chloroquine resistant malaria strains.34 This positive result led to 
the synthesis of a series of aurated chloroquine complexes. The most effective Au(I)-chloroquine 
complex against resistant parasite strains was [Au(PEt3)(CQ)]
1+, but the Au(III)-chloroquine 
complexes generally showed stronger activity than the Au(I) complexes.30  
 
Figure 1.5. Inhibition of P. falciparum growth by gold complexes.33 
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1.2 Zinc Finger Proteins 
It has been estimated that as much as half of the total proteome is made up of proteins that bind 
a metal cofactor in some capacity.35 One of the most abundant metals found in the proteome is 
zinc. In humans, zinc binding proteins are encoded for by up to 10% of the total genome.36–38 The 
functions of zinc as a cofactor are diverse, and include zinc in catalytic, cocatalytic, structural, and 
inhibitory roles.39,40 In proteins that incorporate zinc in a structural role, a zinc(II) atom is generally 
tetrahedrally coordinated to a combination of cysteine and histidine residues.39 This structural 
motif was first observed in the DNA binding domain of the Xenopus laevis transcription factor 
TFIIIA, where it was described as “an unusually small, self-folding domain in which Zn is a crucial 
component of its tertiary structure”. This small domain was described as a “zinc finger”.41 Since 
the discovery of the zinc finger structural motif, zinc fingers have been shown to be involved in a 
number of biological processes. These processes include DNA recognition, RNA packaging, 
transcriptional activation, apoptotic regulation, and protein assembly.36 
Zinc fingers are generally divided into classes based on the zinc coordination sphere.  The most 
common types of zinc fingers fall into three distinct coordination spheres: Cys2His2, Cys2HisCys 
(Cys3His), and Cys4.
36,37,39,42,43 However, recently some additional classifications have been 
discovered.37 The rationale for dividing zinc finger proteins by their zinc coordination sphere 
rather than by the function of the protein or some other metric is that the reactivity of the zinc 
finger protein is intimately tied to the zinc coordination sphere. Therefore, even though zinc finger 
proteins are divided by the zinc coordination sphere rather than protein function, many zinc finger 
proteins with similar functions have the same zinc coordination sphere.42 In addition to differences 
in reactivity between the classes of zinc finger proteins, there is also a significant difference in 
their abundance. One study concluded that while the human genome encodes for 4500 Cys2His2 
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zinc finger domains across 564 proteins, only 17 domains across 9 proteins are encoded.44 The 
inert nature of d10 zinc means that the reactivity of zinc fingers is proportional to the number of 
cysteine residues – the greater the number of nucleophilic cysteine residues, the greater the 
reactivity.45  
Due to the large number of zinc finger proteins observed in nature and their diverse functions, 
many have been studied as potential targets for chemical intervention.  
 
Figure 1.6. Representative zinc finger motifs from each class of zinc finger protein: Cys2His2 
(left), Cys3His (left center), Cys4 (right center), and mixed (right).
36 
 
Cys2His2 Zinc fingers 
One of the most commonly recognized roles of Cys2His2 zinc finger proteins is that of 
transcription factors.39 In fact, the first eukaryotic zinc finger to have its structure elucidated was 
TFIIIA, a transcription factor in Xenopus laevis.46 TFIIIA was found to contain a repeating zinc-
containing structural motif, which bound to DNA and gave rise to the term “zinc finger”.46 TFIIIA 
was found to bind to both the RNA and the DNA gene that encodes for the RNA. This binding 
interaction is only possible because of the specificity imparted by the zinc finger domains.47  
Human transcription factor specificity protein 1 (Sp1) is another zinc finger protein containing 
three Cys2His2 zinc finger domains.
36,39 Sp1 was found to enhance transcription by RNA 
polymerase II as much as 50 fold, and is present in quantities up to 10,000 molecules per cell.48 
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Additionally, the structure of Sp1 together with its DNA binding domain was determined by NMR, 
and it was found that all three zinc finger domains recognize DNA, working together to impart 
selectivity for the GC box binding domain.49 Sp1 expression levels are abnormal in many types of 
cancer, and higher Sp1 expression has been associated with decreased patient survival times in 
some cases.50 This has led to Sp1 becoming the most widely characterized transcription factor in 
mammalian cells, and makes it a highly studied target for chemotherapy development.39 
Cys3His Zinc fingers 
One example of a Cys3His zinc finger that has been widely studied as a chemotherapeutic agent 
is poly(ADP-ribose) polymerase (PARP-1). PARP-1 catalyzes the transfer of ADP-ribose to 
nuclear proteins from NAD.51 PARP-1 was found to contribute to repair of damaged DNA when 
it was shown that cellular NAD content was lowered after treatment with alkylating agents or γ-
radiation. The drop in NAD content is accompanied by an increase in PARP-1 activity.52,53  
 
Figure 1.7. The mechanism of single-strand DNA break repair by PARP. Gold complexes have 
been extensively investigated as PARP inhibitors for the purpose of treating cancer.53 
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PARP-1 localizes to DNA single and double strand breaks and facilitates the assembly of repair 
factors. The zinc finger domains of PARP-1 do not bind specific DNA sequences. Instead, the 
structure imparted by the tetrahedral coordination of zinc recognizes damaged DNA, highlighting 
the diverse set of structure-activity relationships that can be achieved using the zinc finger motif. 
While the N-terminal zinc binding domain is essential to the function of PARP-1, the C-terminal 
zinc binding domain was found to be less important to the function of the protein despite having a 
higher affinity for DNA than the C-terminal domain, and was therefore assumed simply to assist 
in the specificity for certain types of DNA strand breaks. PARP-1 does not bind to the DNA strand 
breaks. Instead, the protein binds to exposed nucleobases that are present in DNA with strand 
breaks, but are also present in other abnormal DNA structures, allowing PARP-1 to interact with 
multiple types of damaged DNA. PARP-1 binds DNA through an interaction that has been termed 
the “phosphate backbone grip” with 3-nucleotide DNA segments, allowing it to interact with 
damaged DNA regardless of the DNA sequence.54 Interestingly, the repair of platinated DNA 
damage by PARP-1 has also been investigated.55 
Cys4 Zinc fingers 
The Cys4 zinc binding motif is the most reactive traditional zinc finger structure due to the 
highly electrophilic nature of the four zinc-coordinating cysteine residues. One example of the 
Cys4 zinc binding motif is the human xeroderma pigmentosum group A (XPA) protein.
56 XPA has 
a single Cys4 zinc finger motif that acts as a recognition site for damaged DNA, and the mutation 
or deletion of the zinc-coordinating cysteine residues has been shown to reduce activity. XPA is a 
part of the nucleotide excision repair process, and functions by recognizing DNA damage and 
recruiting other proteins in order to repair the damaged DNA.57 The increased reactivity of the 
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Cys4 zinc binding motif may aid in the recognition of a number of structurally diverse patterns of 
DNA damage. 
Mixed Zinc Fingers 
In some cases, a single protein may contain more than one type of zinc finger motif.36,37,39 One 
such example is the E3 ubiquitin-protein ligase Mdm2, which contains one Cys3His zinc finger 
and one Cys4 zinc finger.
36 The function of an E3 is to catalyze the formation of a linkage between 
Ubiquitin and its substrate, and in the case of Mdm2 this function is dependent on the C-terminal 
zinc finger.58 Zinc coordination is essential for the E3 function of Mdm2, but has been found to be 
non-essential in the RNA binding function.58,59 
HIV-NCp7 
Cys3His zinc fingers are significantly less common than Cys2His2 zinc fingers, and the 
incorporation of an additional sulfur-containing cysteine into the zinc coordination sphere causes 
them to be more reactive than Cys2His2 zinc fingers as well. One of the most well studied Cys3His 
zinc finger proteins is the HIV nucleocapsid protein (NCp7).60,61 NCp7 has two Cys3His zinc finger 
motifs, and these two zinc fingers are linked by a region of high basicity.61 The zinc in NCp7 is 
bound with very high affinity (Ka = 10
12 - 1014 M-1), as determined by spectrophotometric 
monitoring of cobalt(II) displacement by zinc(II).62 The zinc bound protein was found to have a 
high degree of flexibility, and the zinc finger motifs were found to interact weakly by 1H-
NOESY.63 
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Figure 1.8. The structure of HIV NCp7. The C-terminal zinc finger is highlighted in red. 
 
Like many zinc finger proteins, the primary natural substrate of NCp7 is nucleic acids. The 
structure imparted by zinc coordination forms a “hydrophobic plateau”, which has a strong 
influence on the binding properties of the protein.64 NCp7 binds nucleic acids in both sequence-
specific and nonspecific interactions.65 In particular, NCp7 has a high affinity for guanine 
residues.66 As determined by NMR, this association occurs through a π-π stacking interaction 
between the nucleobases and the aromatic residues on the zinc finger motifs, F16 and W37.44,65,67 
There is a very high degree of conservation, especially among the zinc-coordinating residues, and 
mutations that prevent the binding of zinc result in noninfectious virions.68 
 
Figure 1.9. The structure of NCp7 bound to an RNA substrate.36 
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NCp7 is involved in a number of processes at nearly every point in the viral life cycle.69,70 
These processes include reverse transcription, integration, selective packaging of viral RNA, 
formation of the new viral particle, packaging RNA into a stable dimer, and protection of viral 
RNA against nucleases.69 Primarily, NCp7 is a nucleic acid chaperone, meaning that it helps 
nucleic acid structures to obtain their most thermodynamically stable conformations.70 As 
previously mentioned, the interactions between NCp7 and its substrates can be both specific and 
non-specific. This allows NCp7 to interact with virtually any oligonucleotide substrate between 5 
and 8 nucleobases in length.70 This low-affinity electrostatic binding motif allows for the 
protection of the viral RNA from cellular nucleases by coating the gRNA in a large number of 
molecules (1500-2000) of NCp7.70 In contrast, NCp7 binds strongly and selectively to the SL3 
stem-loop recognition element of the genomic Ψ-RNA, which is highly conserved across HIV-1 
strains.68 
 
Figure 1.10. NCp7 plays a part in numerous viral life cycle processes.69 
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1.3 Current Treatments in HIV 
There are six distinct classes of drugs currently prescribed for the treatment of HIV. These 
classes are nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase 
inhibitors, protease inhibitors, integrase inhibitors, and fusion inhibitors.71  
Reverse transcription is the process by which double-stranded DNA is synthesized from the 
viral single-stranded RNA genome. The protein that carries out reverse transcription is reverse 
transcriptase (RT), which was the target of the first approved anti-AIDS drug, azidothymidine 
(AZT). AZT is a nucleoside reverse transcriptase inhibitor. This class of complexes functions by 
acting as a prodrug, which is converted to a dNTP analog and catalytically incorporated at the 3’- 
end of the DNA primer synthesized by RT. Generally, this inhibits the addition of more 
nucleotides. Conversely, non-nucleoside reverse transcriptase inhibitors inhibit RT by binding to 
an allosteric inhibitory site on RT. Both classes of RT inhibitors suffer from drug-resistance 
mechanisms. In the case of nucleoside RT inhibitors, the enzyme can also work in reverse, acting 
to remove the inhibitor from the DNA strand being synthesized.72 
HIV-1 protease is an enzyme that cleaves Gag and Gag-Pol polyprotein precursors in order to 
produce functioning viral enzymes. Protease is a vital enzyme in the viral life cycle, and its 
involvement in the production of essential enzymes makes it an attractive target for chemical 
intervention. Ten protease inhibitors have been approved by the FDA, and all ten share structural 
and binding similarities. All of the approved protease inhibitors bind in the active site of protease, 
preventing the enzyme from binding its natural substrates by mimicking the substrate transition 
state. However, the protease inhibitors suffer from high toxicity and cause significant adverse side 
effects.73 
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Integrase catalyzes the integration of retroviral genetic material into the DNA of the host cell. 
The integrase enzyme does not have a human homolog, making it an attractive target for chemical 
intervention. Many different classes of compounds have been investigated as integrase inhibitors, 
including hydroxylated aromatics, diketo acids, naphthyridine carboxamides, pyrrolloquinolones, 
dihydroxypyrimidine carbpxamides, and others. This research led to the development of three 
FDA approved integrase inhibitors: Raltegravir, Elvitegravir, and Dolutegravir. All three of these 
complexes function as integrase strand transfer inhibitors, and target the active site of integrase.74 
Fusion is the process in which the virus fuses with the human cell membrane in order to gain 
access to the intracellular human machinery. During fusion, a viral surface protein, HIV-1 surface 
protein 120 (gp120), binds to CD4 receptors on human cells. The interaction between gp120 and 
CD4, the conformation of gp120 is changed, allowing the viral glycoprotein 41 (gp41) to breach 
the cell membrane, forming a pore through which the virus can enter the cell. This process is 
required for viral replication, making it an attractive target for chemical intervention. The 
representative fusion inhibitor is enfuvirtide, a synthetic peptide analog that binds gp41 and 
disrupts its function, preventing the formation of the pore through which the virus enters the cell. 
However, some patients do not tolerate the drug well, and resistance due to amino acid mutations 
on gp41 that prevent drug binding has been observed.75  
1.4 NCp7 as a Drug Target 
The high conservation and large number of viral life cycle processes in which NCp7 is involved 
make it an attractive target for chemical intervention.36,39,42,60,61,76 In fact, all known retroviruses, 
with the exception of spumaretroviruses, contain at least one Cys3His zinc finger.
76 The first 
complexes developed to target the zinc finger motifs of viral nucleocapsid proteins were the C-
nitroso complexes. The complex 3-nitrosobenzamide (NOBA) was found, using 1H-NMR, to eject 
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zinc stoichiometrically from the N-terminal zinc finger of NCp7, and was found to significantly 
reduce both propagation and infectivity of HIV.77 Mechanistically, NOBA acts as an electrophile. 
A nucleophilic zinc-coordinating cysteine residue donates electrons to the C-nitroso group of 
NOBA, resulting in the covalent modification of the cysteine thiolate, preventing zinc 
coordination.78 Other organic complexes investigated for their ability to eject zinc from NCp7 
include the disulfide benzamides, such as 2,2’-dithiobisbenzamide (DIBA), dithiaheterocyclic 
complexes, such as 1,1-dioxide-cis-1,2-dithiane-4,5-diol (Dithiane), and α-carbonyl azoic 
complexes, such as azodicarbonamide (ADA), which were all shown to inhibit NCp7 while 
avoiding unwanted interactions with other zinc finger proteins.79 In general, the mechanisms by 
which the organic zinc ejecting complexes react with NCp7 are thought to be the same.80 These 
complexes were somewhat successful in targeting NCp7, however they suffered from inadequate 
selectivity and poor effective half-life in vivo.81 
 
Figure 1.11. Organic electrophiles that have been investigated for their ability to eject zinc from 
NCp7.36 
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A high throughput screening method was used in order to identify a reversible antagonist of 
the NCp7-polynucleotide interaction, and fluorescein and gallein analogs were found to inhibit 
oligonucleotide recognition of the protein. These complexes were shown to inhibit the activity of 
NCp7 proportionally to their ability to π-π stack with the tryptophan residue on the C-terminal zinc 
finger, as monitored by fluorescence quenching of tryptophan. However, these complexes also 
inhibited unrelated targets. The promiscuity of these complexes was attributed to aggregate 
formation, and disqualified them from significant further investigation as selective inhibitors of 
NCp7.82 
In order to improve on the selectivity of the electrophilic agents and develop complexes that 
are capable of targeting NCp7 selectively, inorganic coordination complexes have been 
investigated for their ability to act as selective agents against both NCp7 and other zinc finger 
proteins. A variety of metal centers have been investigated including nickel, lead, chromium, 
mercury, selenium, palladium, platinum, and gold.36,39 
The current investigation of platinum, palladium, and gold complexes as zinc finger inhibitors 
grew out of the success of cisplatin (cis-[PtCl2(NH3)2]) as a chemotherapeutic agent, and the 
investigation of a diverse number of cisplatin analogs as treatments for both cancer and other 
human diseases has been undertaken. In fact, cisplatin was found to eject zinc from a zinc finger 
protein, DNA polymerase α.83 The interactions of cisplatin and transplatin with the C-terminal zinc 
finger of NCp7 were investigated, and it was found that both isomers caused the ejection of the 
central zinc atom as a result of a replacement of a chloride ligand by a nucleophilic cysteine thiol.84 
Clearly, however, it would be impossible for a chemotherapeutic complex that functions as a DNA 
damaging agent to selectively target a zinc finger protein, but this discovery offered a starting point 
for further investigation.36 Generally, three methods have been proposed for targeting zinc finger 
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proteins in order to treat human diseases: chelation of the central zinc atom, electrophilic attack on 
the zinc-coordinating residues, and interference with the recognition of the protein’s natural 
substrate – generally polynucleic acids.36  
 
Figure 1.12. Interactions of cisplatin with the C-terminal zinc finger of NCp7 as monitored by 
CD (left) and Fluorescence quenching (right).84 
 
The π-π stacking interactions between nucleobases and the aromatic amino acids of proteins 
has been extensively studied and characterized.85,86 Additionally, the realization that N-
quaternization (via protonation or methylation) of a nucleobase increases the π-π stacking ability 
of the nucleobase with an aromatic amino acid provided an excellent starting point for the 
development of a selective NCp7 inhibitor.85,87 The enhancement of π-π stacking ability of 
nucleobases was expanded to N-quaternization via metalation. The first system examined was the 
[Pt(dien)(Nucleobase)]2+ system.88 The nucleobase analogs initially investigated were 9-
ethylguanine, 1-methylcytosine, 5’-guanosine monophosphate, and 5’-cytosine monophosphate, 
and the diethylenetriamine chelate was selected in order to eliminate a labile leaving group and 
ensure that only non-covalent hydrogen bonding interactions were possible. Fluorescence 
quenching of tryptophan showed a significant enhancement of the association constant for the 
platinated nucleobases over the free analogs, and upfield shifts of the 1H-NMR signals of N-
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acetyltryptophan upon interaction with the platinated nucleobases were indicative of a π-π stacking 
interaction.88 
The faster hydration kinetics of palladium complexes (relative to their platinum counterparts) 
led to the investigation of the Pd(II) analogs of the [Pt(dien)(Nucleobase)]2+ complexes.89 In 
contrast to their Pt(II) analogs, the Pd(II) complexes formed covalent analogs with N-
acetyltryptophan as shown by NMR and mass spectrometry, highlighting the increased kinetic 
lability of the Pd(II) metal center.89 Theoretical studies comparing these complexes to the free 
nucleobases and alkylated nucleobases showed a significant increase in the overlap between the 
N-acetyltryptophan HOMO and the nucleobase LUMO upon metalation relative to the free and 
alkylated nucleobases.90  The enhancement of the orbital overlap is the source of the increased 
association for the metallated nucleobases over the free ligands.88–90 It was also postulated that 
steric interactions with the metal center, which is relatively bulky, and rotation around the metal-
nucleobase bond also have an impact on the π-π stacking ability of complexes of this nature.90 
Evidence for the presence of rotamers found in the platinum complexes and the great deal of steric 
modification that is possible around a metal center led to the further investigation of complexes of 
this form as potential selective inhibitors of NCp7.88 
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Figure 1.13. N-Quaternization improves the overlap of the N-acetyltryptophan HOMO and 
nucleobase LUMOs.90 1 – [Pd(dien)(1-MeCyt)]2+, 2 – [Pt(dien)(1-MeCyt)]2+, 3 – [Pd(dien)(9-
EtGua)]2+, 4 – [Pt(dien)(9-EtGua)]2+. 
 
A series of trans-planar amine platinum complexes showed a strong preference for the sulfur 
containing amino acid cysteine over methionine. This result is expected due to the high lability of 
the chloride ligands and the high nucleophilicity of the cysteine thiol.91 The lead complex, trans-
[PtCl(9-EtGua)(py)2]
2+, was also found to eject zinc small molecule models for the NCp7 zinc 
finger.92 This complex was later found to eject zinc from the C-terminal zinc finger of NCp7. This 
was determined through the use of circular dichroism, where a loss of tertiary structure indicative 
of zinc ejection was observed, and by mass spectrometry, where it was shown that the complex 
ejected zinc and bound 2:1 in the form [Pt(py)2]2-peptide. It was proposed that the ejection of zinc 
occurred by a three step mechanism: non-covalent recognition of the protein by a π-π stacking 
interaction between the tryptophan and the platinated 9-ethylguanine, displacement of the chloride 
and covalent binding to a cysteine thiol, and zinc ejection concomitant with displacement of the 
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platinated nucleobase and coordination to a second cysteine thiol.93 The complex [Pt(dien)(9-
EtGua)]2+ was also investigated, and was found to interact noncovalently with the C-terminal zinc 
finger of NCp7 – zinc ejection and covalent adduct formation were not observed.93 The 9-EtGua 
and DMAP analogs were found to quench tryptophan fluorescence more effectively than a number 
of other N-heterocycles, leading to the use of these N-heterocycles in many of the further 
investigations into complexes containing N-heterocycles.94 
 
Figure 1.14 The structures of platinum(II), palladium(II), and gold(III) complexes containing a 
diethylenetriamine chelating ligand that were investigated as NCp7 inhibitors.94 
 
The [Pt(dien)(9-EtGua)]3+ system was further investigated to show that DNA could be 
metallated in order to disrupt the interaction between DNA and NCp7 by inhibiting the recognition 
of the polynucleotide by the protein.95 The differences in the substitution kinetics between 
[MCl(dien)]n+ and [MCl(terpy)]n+ (M = Pt(II), Pd(II), Au(III); terpy = 2,2’:6’,2’’-terpyridine) were 
also investigated. In all cases, the labile chloride ligand resulted in covalent adduct formation with 
the peptide, but it was proven that the modulation of the metal center and the chelate were a viable 
platform for further investigation.96 
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Figure 1.15. Interaction of [Pt(dien)(9-EtGua)]2+ with the C-terminal zinc finger of NCp7 (top). 
Noncovalent adducts are not formed until MS/MS is performed (bottom).93 
 
The noncovalent analogs formed by the complex [Pt(dien)(9-EtGua)]2+ led to the study of 
analogs using the more reactive gold(III). The complexes [Au(dien)(DMAP)]3+ and [Au(dien)(9-
EtGua)]3+ were found to exhibit 1H-NMR spectral differences over a range of pH values. These 
spectral changes were attributed to the deprotonation of the central amine, assigned a pKa value of 
3.3 for the 9-ethylguanine complex, the deprotonation of the 9-ethylguanine N1, assigned a pKa 
value of 5.3, and finally dissociation of the 9-ethylguanine ligand, assigned a pKa value of 7.5. 
Tryptophan fluorescence quenching was used in order to show that these complexes had a stronger 
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Table 1.1. Peak potential values for the reduction of gold(III) complexes. Reduction was 
determined at a platinum electrode (vs Ag/AgCl), in 50 mM phosphate buffer, 4 mM NaCl, 
pH 7.4.97 
association constant with N-acetyltryptophan than their platinum(II) and palladium(II) 
counterparts. The use of the AuN4 coordination sphere was also found to stabilize the gold(III) 
oxidation state relative to the AuClN3 coordination sphere, and the stabilization was found to be 
proportional to the basicity of the N-heterocyclic ligand. This stabilization indicates that AuN4 
complexes of this nature would be less likely to interact with sulfur-containing biomolecules, and 
warranted their further investigation as selective inhibitors of NCp7.97 
Complex Ep (V) 
[AuCl(dien)]2+ -0.280 
[Au(dien)(9-EtGua)]3+ -0.349 
[Au(dien)(DMAP)]3+ -0.328 
[AuCl(N-MeDien)]2+ -0.232 
[Au(N-MeDien)(9-EtGua)]3+ -0.263 
[Au(N-MeDien)(DMAP)]3+ -0.238 
 
 
In a later work, 1H-NMR studies showed a reduced reactivity with the sulfur containing amino 
acids N-acetylmethionine and N-acetylcysteine for the AuN4 complexes with respect to the 
AuClN4 complexes, with signals representing substitution by N-acetylmethionine appearing after 
15 hours. The substitution by the thiol containing N-acetylcysteine is more rapid than the thioether 
containing N-acetylmethionine. The fluorescent emission of the N-terminal zinc finger was 
quenched by both the N-heterocycle containing complexes and the chloride containing complex, 
indicating quenching occurred through loss of the central zinc atom and a change in peptide 
structure, rather than through a π-π stacking mechanism. This change in structure was confirmed 
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by circular dichroism and mass spectrometry. Interaction with the complexes caused the circular 
dichroism spectrum to shift from a spectrum characteristic of zinc finger (positive band at 220 nm 
and slight negative band at 195 nm) to random coil type structure (decrease in positive band 
intensity, increase in negative ellipticity, slight blueshift) very rapidly. Mass spectrometric results 
showed zinc ejection and formation of “gold fingers” immediately upon interaction.98 
Interestingly, however, recent results obtained by EXAFS and XANES have showed that the AuN4 
coordination sphere is maintained longer than previously expected.99 
 
Figure 1.16. Differences in interactions of [AuCl(dien)]2+ and [Au(dien)(DMAP)]3+ with 
NCp7 as determined by EXAFS.99 
 
In further studies were designed to probe the ability of these complexes to prevent NCp7-
polynucleotide binding. Mass spectrometry of a solution of NCp7 that had been incubated with 
[Au(dien)(9-EtGua)]3+ to which SL2 was added showed only uncomplexed SL2. Additionally, 
mass spectrometry of a solution of complexed NCp7-SL2 to which [Au(dien)(9-EtGua)]3+ was 
added showed a significant amount of free SL2, indicating that [Au(dien)(9-EtGua)]3+ was capable 
of both preventing NCp7 from recognizing its natural substrate, and that the complex could disrupt 
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the complex of NCp7 and its natural substrate once the complex had already formed. These mass 
spectrometry results were also confirmed using an electrophoretic mobility shift assay and a 
fluorescence polarization assay.100 
 
Figure 1.17. [Au(dien)(9-EtGua)]3+ causes dissociation of the SL2-NCp7 complex.100 
 
A similar strategy was used in the attempt to design a gold(I) complex with the ability to 
selectively inhibit NCp7 as well. Complexes of this form were developed to leverage the success 
of auranofin as an arthritis treatment coupled with the incorporation of the N-heterocycle 
recognition element utilized in the [M(dien)(N-heterocycle)]n+ type complexes. Complexes of the 
form [(PPh3)Au(N-heterocycle)]
+ formed a white precipitate immediately upon interaction with 
N-acetylcysteine, indicating rapid N-heterocycle displacement. Upon interaction with the C-
terminal zinc finger motifs of NCp7 and Sp1, the gold was observed bound to the apopeptide with 
the triphenylphosphine ligand still bound. This was the first example of a gold complex bound to 
these zinc finger proteins without total ligand dissociation. Formation of gold fingers was also 
observed. These results further illustrate that tuning the electronic and steric properties around the 
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metal center can have dramatic effects on the reactivity of coordination complexes with zinc finger 
protein targets.101 Additional evidence that reactions with zinc finger proteins are modulated by 
the metal coordination sphere was found in the complexes in which 2-mercaptothiazole and 
cyanide were used as ligands in place of the N-heterocycle. In one such complex, it was found that 
the phosphine ligand may dissociate first, due to the high trans effect of the 2-mercaptothiazole 
ligand.102 
 
Figure 1.18. The structures of gold(I) complexes investigated as NCp7 inhibitors.101,102 
 
1.5 The Use of Gold Complexes to Target Zinc Finger Proteins 
In addition to the study of gold complexes as selective inhibitors of NCp7, gold complexes 
have also been investigated as selective inhibitors of other zinc finger proteins.103 Auranofin, 
[Au(bpy)Cl2]
1+, and [Au(phen)Cl2]
1+ (bpy = bipyridine, phen = 1,10-phenanthroline) were 
investigated for their ability to inhibit PARP-1, and were found to inhibit the protein more 
effectively than the “benchmark” inhibitor, the organic complex 3-aminobenzamide. The gold(III) 
complexes rapidly lost all ligands and formed “gold-finger” type structures more quickly than 
auranofin, a gold(I) complex, highlighting the enhanced reactivity of the gold(III) oxidation state. 
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Additionally, both the gold(I) and the gold(III) complexes formed adducts with the protein more 
rapidly than the representative platinum(II) (cisplatin), ruthenium(III) (NAMI-A), and 
ruthenium(II) (RAPTA-T) complexes.104 
The ability of gold complexes to inhibit PARP-1 was further investigated through the synthesis 
of a library of gold complexes that contained multidentate N-donor chelating ligands. It was found 
that the gold complexes that displayed cytotoxic effects, such as the dinuclear [Au2{2-(2-
pyridyl)imidazolate}(PPh3)2]
1+ also displayed the ability to inhibit PARP-1 activity in cisplatin 
sensitive cells, while the complex [Au(2-phenylimidazole)(DAPTA)] (DAPTA = 3,7-diacetyl-
1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane), which did not display cytotoxicity was also unable 
to inhibit PARP-1.105 Additionally, the analog of [Au(bpy)Cl2]
1+ containing the bidentate chelating 
ligand 2-((2,2’-bipyridin)-5-yl)-1H-benzimidazol-4-carboxamide was found to preferentially 
target PARP-1 over the traditional target for complexes of this nature, thioredoxin reductase.106 
Gold(I) complexes containing N-heterocyclic carbene ligands were also investigated for their 
cytotoxic properties. These complexes were thought to interact with PARP-1 in a non-covalent 
manner without loss of the gold-bound ligands.107 
1.6 Gold Complexes Containing a C-Donor Ligand 
Research into methods by which to further stabilize the gold(III) oxidation state has evolved 
into investigation of complexes containing one or more gold-carbon bonds.14,108 While many of 
the complexes containing gold-carbon bonds have been developed as chemotherapeutic agents, 
with the thioredoxin/thioredoxin reductase system as the main target, some interesting protein 
interactions have been discovered. A reductive elimination mechanism by which the C-donor 
ligand of complexes containing 2-arylpyridine or an analog as a chelating ligand is transferred to 
a cysteine thiol forming a thioether was discovered. The proof of cysteine arylation was obtained 
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using a number of short cysteine-containing peptide sequences, and it was found that the reaction 
proceeded over a wide range of pH and temperature. Cysteine arylation by these complexes was 
also achieved on the larger proteins bovine serum albumin and human serum albumin, proving 
that bioconjugation on a full protein was possible.109 This mechanism is of particular importance, 
as it parallels the mechanism by which the E. coli N-Ada protein repairs DNA which has been 
damaged by alkylation.110,111 While a great deal of investigation has been conducted on palladium-
catalyzed cysteine bioconjugation, the analogous gold-catalyzed reactions have been studied to a 
significantly lesser extent.112–115 A recent example of a gold complex, [(Me-DalPhos)Au(R)Cl]1+ 
(Me-DalPhos = Ad2P(o-C6H4)NMe2, R = aryl), showed that bioconjugation of a number of 
different arylating ligands is possible, including an chemotherapy drug, an affinity tag, and a 
fluorescent dye. Cysteine arylation was confirmed on a short peptide sequence and on glutathione, 
a target of biological relevance, by LC-MS.116 
 
Figure 1.19. Proposed mechanism of DNA repair by the N-Ada enzyme. Alkylated DNA is 
repaired by alkylation of a zinc-coordinating cysteine residue.37 
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In order to probe the reactivity of complexes with a gold-carbon bond in zinc finger proteins, 
the complex [Au(bnpy)Cl2] (bnpy = 2-benzylpyridine) was synthesized. The interactions of 
[Au(bnpy)Cl2] were compared to the analogous N^N complexes [Au(bpy)Cl2]
1+, [Au(4,4’-
Me2bpy)Cl2]
1+, and [Au(phen)Cl2]
1+. The interaction between the small molecule model N-
acetylcysteine and [Au(bnpy)Cl2]
1+, the cysteine arylation product was observed. It was proposed 
that this arylation mechanism requires a cis orientation between the coupling partners in order for 
the reductive elimination to proceed.117 
 
Figure 1.20. General scheme of zinc finger arylation by [Au(bnpy)Cl2]. X represents an N-
donor, likely from the peptide.117 
 
The reaction of [Au(bnpy)Cl2]
1+ with the C-terminal zinc finger motif of NCp7 showed the 
production of the cysteine arylation product after 48 hours, while the N^N complexes showed 
products typical of interaction with a gold complex containing a labile chloride ligand. In contrast, 
reaction with glutathione did not produce the cysteine arylation product, showing that the 
microenvironment of the cysteine residue is important to the ability of the cysteine to be arylated. 
The ability of the C-terminal zinc finger to be covalently modified by a gold complex shows the 
potential for the development for a selective complex to covalently modify NCp7.117 
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Figure 1.21. Interaction of [Au(bnpy)Cl2] with the C-terminal zinc finger of NCp7 after 48 
hours of incubation.117 
 
1.7 Dissertation Outline 
It is the goal of this dissertation to expand on the chemistry of gold(III) complexes and their 
potential uses as inhibitors of HIV NCp7 so that they might be competitive with the lead 
platinum(II) complex [Pt(dien)(xanthosine)]2+ and the lead organic compounds that were 
discovered to interact with NCp7 through a high throughput screening process.118,119 The 
promiscuity of the previously reported [Au(dien)(N-heterocycle)]3+ complexes necessitates further 
tuning of the electronic and steric environment of the AuN4 coordination sphere if a selective 
inhibitor of NCp7 is to be developed. Chapter 2 discusses the attempt to develop an AuN4 complex 
using the more sterically hindered chelating ligand di-(2-picolyl)amine in order to slow the 
reaction with NCp7 and prevent interactions with undesirable biomolecules such as glutathione, 
creating selectivity for NCp7. The gold(III) chloride complexes based on this chelate were 
investigated for their interactions with NCp7 and compared with the platinum(II) analogs. 
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Given the increased affinity of 1-methylcytosine for N-acetyltryptophan relative to the other 
previously studied nucleobase analogs, such as 9-ethylguanine and 4-dimethylpyridine, it is natural 
that the gold(III) analog of the previously studied [Pt(dien)(1-MeCyt)]2+ and [Pd(dien)(1-
MeCyt)]2+ be investigated. The synthesis, characterization, and interactions with the C-terminal 
zinc finger of NCp7 are discussed in detail in Chapter 3. 
The emergence of organometallic gold complexes has shown their potential for use in a variety 
of applications. Chapter 4 aims to investigate the interactions between the organometallic complex 
[AuCl2(dampa)] and biologically relevant molecules, including NCp7. The comparison of the 
interactions between this complex and the similar [Au(bnpy)Cl2] are compared and contrasted. In 
addition, the novel triphenylphosphine-containing complex [AuCl(dampa)(PPh3)]
1+ was 
investigated. The synthesis, characterization, X-ray crystal structure, and interactions of this 
complex with biologically relevant molecules, including NCp7, are detailed.  
Additional data, including the attempted synthesis of sterically hindered analogs of 
[Au(dien)(N-heterocycle)]3+ complexes and the investigation of the binding differences between 
gold(I) and gold(III) complexes with polypeptides are described in Chapter 5. Chapter 6 will detail 
the recovery of residual platinum from laboratory waste. Submitted and published works are in a 
format as close to the submitted format as possible. 
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Chapter 2: Interaction of the HIV NCp7 protein with 
platinum(II) and gold(III) complexes containing 
tridentate ligands 
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**As supporting author for the following work, I performed all work pertaining to the synthesis 
and characterization of the gold(III) complexes described and all investigation into the attempted 
synthesis of AuN4 complexes. Additionally, I performed all analyses using the gold(III) complexes 
and played a significant role in the interpretation of the mass spectrometry data obtained from the 
interactions of gold(III) complexes with zinc fingers. 
2.1 Abstract 
Herein, we describe the interactions of [MCl(N3)]
n+ complexes [M = Pt2+ (n = 1) and Au3+ (n 
= 2); N3 = tridentate ancillary ligands: bpma (bis(2-pyridylmethyl)amine) or Mebpma (bis(2-
pyridylmethyl)methylamine)] with the C-terminal finger of HIV-1 nucleocapsid protein NCp7 
(ZF2). Substitution-inert analogs [Pt(N3)L]
2+ were prepared with 9-EtGua and substituted 
pyridines to examine stacking interactions with tryptophan and the tryptophan-containing ZF2 and 
“full” 2-finger HIVNCp7. The use of the bpma and Mebpma ligands gives slightly higher affinity 
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than analogous [Pt(dien)L)]2+ complexes.  The dmap-containing complexes have the greatest 
affinity for the Trp residue in N-AcTrp and ZF2 peptide. Complex PtL1a has the greatest Ka when 
compared with other known Pt2+ analogues; [Pt(dien)(9-EtGua)]2+ < PtL2c <[Pt(dien)(dmap)]2+< 
PtL2a < PtL1a. The Ka value was also obtained for the full NCp7 peptide with PtL1a (ca. 
40.6±1.0). In addition, the ESI-MS spectrum of the mixture of the ZF2 with this complex confirms 
formation of a 1:1 PtL1a:ZF adduct. The reactivities of the [MCl(Mebpma)]n+ (PtL1 and AuL1) 
complexes with NCp7 ZF2 (C-terminal of the NCp7 Zinc finger domain) were investigated by 
ESI-MS. When compared with the known dien-containing analogs [MCl(dien)]n+, the 
[MCl(Mebpma)]n+ complexes are far more reactive. The initial product of reaction of PtL1 with 
ZF2 results in loss of all ligands and release of zinc to give the platinated apopeptide {PtF}. This 
is in contrast to [PtCl(dien)]+ where {Pt(dien)}-peptide adducts are observed.  The reaction of the 
Au3+ complex AuL1 with ZF2 gives AuxF
n+ species (x =1,2,4) with loss of all ligands. The 
[Pt(N3)L]
2+ complexes PtL1a, PtL2a, and PtL2c were inert when incubated with N-AcCys, 
whereas the precursor compounds [PtCl(N3)]Cl (PtL1, N3= Mebpma; PtL2, bpma) reacted readily 
with the sulfur-containing amino acid. 
2.2 Introduction 
The HIV nucleocapsid (NCp7) protein has an amino acid sequence highly conserved in all 
HIV retrovirus subtypes. NCp7 has important roles in the viral life cycle, especially in the 
assembly and reverse transcription stages.1,2 Its functions are intimately related to the protein 
structure. The two zinc finger (ZF) domains in the NCp7 sequence, both of the CCHC-type, are 
responsible for the protein folding that allows non-covalent interactions between amino acid 
residues and the viral RNA. The π-π stacking between ZF Trp37 and the RNA guanine is one of 
the most important interactions in the NCp7/RNA adduct.1,3,4 Deletion of Trp37 can lead to loss 
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of protein function causing HIV inhibition.5 Due to these characteristics the NCp7 ZF has been 
investigated as a target in anti HIV therapies.1,2,6–10 To enhance selectivity over other zinc fingers, 
and zinc proteins in general, the aromatic amino acids Phe(ZF1) and Trp(ZF2) can be designated 
as molecular targets whereby ligands (drugs) capable of π-π stacking interactions, especially with 
the essential tryptophan, can inhibit DNA/RNA recognition.11,12  
We are actively engaged in designing metallated-N-heterocyclic complexes targeted to 
tryptophan recognition, to examine eventual interruption of the NCp7-RNA interaction.12-16 
Metallation, along with protonation and alkylation, of purines and pyrimidines can increase the 
affinity for π-π stacking with tryptophan over the “parent” nucleobase.13,17 The same trend is seen 
for other aromatic heterocycles, e.g. 4-dimethylaminopyridine (dmap).18 For the simple amino 
acid, the complexes [Pt(dien)(dmap)]2+, [Au(dien)(dmap)]3+ and [Au(N-Medien)(dmap)]3+ 
showed the highest association constants among other N-heterocyclic containing complexes.18,19 
The use of formally substitution-inert MN4 systems is critical to this design as they enable initial 
“non-covalent” recognition between the metallated nucleobases and tryptophan, followed by 
nucleophilic attack of a zinc-finger cysteine at the metal site. The mechanism of action of trans-
[PtCl(py)2(9-EtGua)]
+ (which has incipient HIV inhibitory action and ejects Zn2+ of the ZF 
domain) has been proposed to involve the two steps of target recognition (Trp stacking) followed 
by target “fixation” (Pt-Cys binding).14 Use of MN4 systems could allow for greater selectivity 
where the Pt-N bond is more substitution-inert than its Pt-Cl counterpart.20  
In this paper we describe and compare the chemistry and biology of Pt2+ and Au3+ complexes 
containing tridentate ligands based on bis(2-pyridylmethyl)amine (bpma) and further compare 
their properties with the previously studied diethylenetriamine (dien) chelates. Pt2+, Pd2+ and Au3+ 
complexes containing the bpma ligand have been extensively studied.21–27 Herein we describe the 
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reactions of formally isostructural and isoelectronic complexes [MCl(N3)]
n+ (M = Pt, n = 1; Au, n 
= 2; N3 = Mebpma (bis(2-pyridylmethyl)methylamine)) (Figure 2.1) with the simple amino acid 
N-AcCys and the C-terminal finger NCp7(ZF2) that result in Zn2+ ejection and metallation of the 
apoF2. Furthermore, we show that the stacking interactions of the platinum(II) complexes 
[Pt(N3)L]
2+ (L = N-heterocyclic ligand: 4-dimethylaminopyridine (dmap), 9-ethylguanine (9-
EtGua) and 4-methylpyridine (4-pic)) with tryptophan and the ZF2 can be tuned by judicious 
choice of both tridentate ligand carrier, N3 (Mebpma instead of bpma) and L (Figure 2.1). The 
properties of the bpma and Mebpma complexes are also compared with previous results using the 
diethylenetriamine (dien) chelate. These results open new avenues in the search for potential and 
selective candidates for HIV inhibition. 
2.3 Results and Discussion 
Synthesis and Characterization of the chloro-complexes [PtCl(N3)]Cl  and [AuCl(N3)]Xn (N3 = 
Mebpma and bpma). 
[PtCl(Mebpma)]Cl (PtL1) was synthesized from cis-[PtCl2(DMSO)2] and Mebpma (bis(2-
pyridylmethyl)methylamine), in CH2Cl2 in 60% yield. The analogous bpma (bis(2-
pyridylmethyl)amine) [PtCl(bpma)]Cl (PtL2) was obtained in similar yields (98%) by the same 
method. The bpma compound was previously described in the literature through synthesis in water 
from [PtCl2(COD)].
23,26 The analogous gold(III) complex [AuCl(Mebpma)](PF6)2 (AuL1) was 
synthesized from hydrogen tetrachloroaurate hydrate and Mebpma, as previously described for the 
analogous Bbpma (bis(2-pyridylmethyl)benzylamine) compound,25 and isolated in 53.5% yield. In 
the case of the bpma ligand, the pale yellow [AuCl(bpma)](OTf)2
 (AuL2) is thermally unstable 
with a strong tendency to deprotonation of the “central” N.25 The red (AuL2) was isolated in the 
amide form as the [AuCl(bpma-H)](PF6) salt as described previously.
25 The related compounds 
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[PtCl(dien)]Cl and [AuCl(dien)]Cl2 were also prepared for comparison following literature 
methods.29,30,31  
 
 
 
1H Nuclear Magnetic Resonance spectroscopy. 
In the 1H NMR spectra of the two free ligands, obtained in D2O, the CH2 signal (H7) appears 
as a singlet, at δ 3.55 (Mebpma) and 3.76 (bpma). After coordination, the signals are shifted 
downfield and due to restricted rotation the CH2 signal becomes a doublet of doublets δ 4.60 and 
5.17 for PtL1 and δ4.65 and 4.96 for PtL2. (Table 2.1, Figure 2.2). The diastereotopic protons are 
designated as endo-CH and exo-CH protons (Figure 2.3a).27 The same trend is observed for the 
AuL1 Mebpma complex (Figure 2.4). The spectrum, obtained in dmf-d7 due to low solubility of 
the complex in water, shows a singlet at δ 3.75 (free Mebpma) and the doublet of doublets at δ 
Figure 2.1. Structures of N3 ligands, the platinum(II) and gold(III) complexes investigated 
in this study and of [MCl(dien)]Cln (M = Pt, n = 1; Au, n = 2). 
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5.47 and 6.35 (AuL1). As previously reported, the room temperature 1H NMR spectrum of AuL2 
does not exhibit the split CH2 signal due to the amine-amide equilibrium and a broad singlet is 
observed.25 Similarly, the amide-form [AuCl(bpma- H)](PF6) shows a sharp singlet at δ 4.40 ppm 
(Figure 2.4). 
 
 
  
Figure 2.2. 1H NMR spectra of the free ligands Mebpma and bpma and their 
platinum(II) complexes PtL1 and PtL2. 
 
55 
 
 
 
 
  
Figure 2.3. a) Designation of the endo-CH(blue) and the exo-CH(red) protons. 
b) Rotamers for PtL2c.1 
 
Figure 2.4. 1H NMR spectra for ligands and [AuCl(Mebpma)]2+ (AuL1) and [AuCl(bpma-
H)]+Au(L2-H). 
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Compounda H6 H5 H4 H3 H7 H9 
Mebpma 
 
8.34 
(d, 8.0) 
7.25 
(d, 8.0) 
7.72 
(td, 8.0) 
7.29 
(d, 8.0) 
3.55 
(s) 
2.11  
(s) 
PtL1  
 
8.76 
(d, 4.0) 
7.51 
(t, 8.0) 
8.14 
(t, 8.0, 4.0) 
7.65 
(d , 8.0) 
4.60/5.17 
(dd, 16.0) 
3.05  
(s) 
bpma  
 
8.35 
(d, 4.0) 
7.24 
(t, 8.0) 
7.72 
(td, 8.0) 
7.30 
(d, 8.0) 
3.76 
(s) 
- 
 
PtL2 26  
 
8.53 
(d, 4.0) 
7.21 
(t, 8.0) 
7.98 
(td, 8.0; 4.0) 
7.52 
(d, 8.0) 
4.65/4.96 
(dd, 16.0) 
- 
 
Mebpma*  
 
8.54 
(d, 3.0) 
7.29 
(td, 6.0, >1.0) 
7.82 
(td, 9.0, 3.0) 
7.61 
(d, 6.0) 
3.75 
(s) 
2.25 
(s) 
AuL1* 
 
9.13 
(d, 6.0) 
8.13 
(t, 6.0) 
8.72 
(t, 6.0) 
8.32 
(d; 9.0) 
5.47/6.35 
(dd, 15.0) 
3.94 
(s) 
bpma * 
 
8.54 
(d, 6.0) 
7.26 
(td, 6.0, 3.0) 
7.79 
(td, 6.0, >1.0) 
7.52 
(d, 9.0) 
3.92 
(s) 
- 
 
Au(L2-H) 25* 
 
9.14 
(d, 6.0) 
7.96 
(m, 6.0) 
8.55 
(m, 9.0) 
8.21 
(d, 9.0) 
4.40 
(s) 
- 
 
AuL2 
 
9.15 
(dd, 6.0, >1.0) 
8.00 
(td, 9.0, >1.0) 
8.57 
(td, 9.0, >1.0) 
8.19 
(d, 9.0) 
6.00 
(br s) 
- 
 
a: δ(Pt) for PtL1 = -2331.9 ppm; for PtL2 = -2301.8 ppm rel. to Na2PtCl6 in D2O (See 
Experimental Section).  *The spectra of the Pt2+ complexes were obtained in D2O and those of the 
Au3+ complexes in dmf-d7. Spectra of the free ligands were obtained in both solvents for 
comparison. See Figs. S1 and S3. br = broad, s = singlet, d = doublet, dd = doublet of doublets, t 
= triplet, td = triplet of doublets, m = multiplet. The values in parenthesis are multiplicity and 
coupling constants (Hz).  
 
Metal coordination leads to characteristic downfield shifts of the aromatic hydrogens of both 
ligands, due to the decrease of electron density on the pyridine rings. The same occurs for the CH3 
Table 2.1. 1H NMR shifts (ppm) for the [MCl(N3)]
n+ complexes PtL1, PtL2, AuL1, AuL2, 
Au(L2-H) and for the free N3 ligands (Mebpma and bpma). 
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hydrogen signal (H9) of the methylated ligand in PtL1 and AuL1 (Table 2.1). In all cases the 
relative changes in shift {δ(L) - δ(ML)} are uniformly higher for the Au3+ versus Pt2+ reflecting 
the greater electronegativity of the Au3+ center.  The pKa for the amine-amide equilibrium in the 
Au(III)-bpma compound has been estimated to be 3.5,25 comparable to that measured for 
[AuCl(dien)]2+ in the range of 4.0-4.7 depending on conditions.32,33 In this respect, the behavior of 
Au3+ is in stark contrast to the formally isoelectronic Pt2+ where a pKa of 11.94 has been measured 
for [Pt(dien)(DMSO)]2+.34 
Synthesis and Characterization of N-heterocycle-complexes [Pt(N3)L]Cl2 (N3 = Mebpma, L = 
dmap; N3 =  bpma, L = dmap, 4-pic or 9-EtGua). 
The substitution reactions of the [MCl(N3)]
n+ complexes with L = N-heterocycles were 
investigated to prepare formally substitution-inert complexes of the type [Au(N3)L]
3+ and 
[Pt(N3)L]
2+ for  model studies for recognition and fixation on the zinc finger. The novel anticipated 
platinum(II) species [Pt(Mebpma)(dmap)]Cl2 (PtL1a)  [Pt(bpma)(dmap)]Cl2 (PtL2a), 
[Pt(bpma)(4-pic)]Cl2 (PtL2b) and [Pt(bpma)(9-EtGua)]Cl2 (PtL2c)  were obtained in good yields 
from the reactions with the respective N-heterocycles in H2O, without the necessity for activation 
of the respective precursors PtL1 and PtL2 with AgNO3, (Scheme 2.1). The reaction of PtL2 with 
9-EtGua and Guanosien (Guo) has been previously investigated by 1H NMR spectroscopy in 
aqueous solution but the products were not isolated.27 
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The 1H NMR spectrum of the 9-EtGua-containing complex PtL2c (Table 2.2 and Figure 2.5) 
evidences the presence of anti and syn rotamers related to two different spatial orientations of the 
NH group which interconvert by rotation about the Pt−NH bond.27  In the 1H NMR spectra of the 
dmap (PtL1a and PtL2a) and 4-pic-containing complexes (PtL2b) the H2’ and H3’ hydrogen 
signals of the substituted pyridines appear as broad singlets: at δ 8.92 (H2’) and 7.67 (H3’) for 
PtL2b and at around δ 8.40 (H2’) and 6.85 (H3’) for the [Pt(N3)(dmap)]2+ compounds PtL1a and 
PtL2a (Table 2.2). This is due to restricted rotation of the coordinated N-heterocycle, where 
different ligand conformations contribute to broaden the signals. The H2’ and H3’ signals become 
narrower, more intense and slightly deshielded upon increasing the temperature to 60ºC (Figure 
2.6). After cooling to 20°C (starting temperature), the NMR spectra exhibited the same profile as 
before heating. These results are consistent with the refined crystal structure of the 
[Pt(bpma)(py)]2+ cation where the pyridine ring is almost perpendicular to the PtN3(bpma) plane, 
Scheme 2.1. Synthetic route and numbering for the [Pt(N3)L]Cl2 compounds. 
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with the capacity for steric hindrance – indeed broad signals of the pyridine protons were also 
reported for the similar [Pt(bpma)(4-pic)]2+ cation.26 
 
The 195Pt NMR spectra of all complexes show the signals expected for the [PtCl(N3)]
+ and 
[Pt(N3)L]
2+ platinum(II) coordination spheres.35,36 For the chloride species signals are seen at δ -
2331.9 ppm (PtL1) and δ -2301.8 ppm (PtL2) (See Table 1). Substitution of Pt-Cl by the N-donor 
results in expected chemical shifts to δ -2413.1 (PtL1a), δ -2401.5 (PtL2a) and δ -2405.5 (PtL2b)  
while the spectrum of PtL2c exhibits two signals at δ -2362.7 and δ -2379.1 ppm in accordance 
with the presence of syn and anti rotamers (Table 2.2).27 
Figure 2.5. 1H NMR spectrum of PtL2c. 
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NMR Shifts (ppm), Multiplicity and Coupling Constants (Hz) 
Compound 195Pt NMR N3 hydrogens (Mebpma and bpma) L hydrogens 
  H3 H4 H5 H6 H7 H9 H2’ H3’ 
H6’ 
(H5’ for 4-pic) 
PtL1a 
 
-2413.1 
7.73 
(m) 
8.18 
(td, 8.0, 4.0) 
7.43 
(t, 8.0) 
7.73 
(m) 
4.66 
(d, 16.0) 
5,17 
(d,16.0) 
3.06 
(s) 
8.38 
(br s) 
6.84 
(br s) 
3,15 
(s) 
PtL2a 
 
-2401.5 
7.67 
(m) 
8.13 
(td, 8.0, 4.0) 
7.37 
(t, 8.0) 
7,67  
(m) 
overlapped - 
8.46 
(br s) 
6.85 
(br s) 
3,15 
(s) 
PtL2b 
 
-2405.5 
7.67 
(d, 8.0) 
8.15 
(td, 8.0, 4.0) 
7.35 
(t, 8.0) 
7.56 
(d, 4.0) 
overlapped - 
8.92 
(br s) 
7.67 
(br s) 
2.58 
(s) 
        H8’ H10’ H11’ 
PtL2c 
 
-2362.7; 
-2379.0 
7.57-7.66 
(m) 
8.12 
(t, 8.0) 
7.33 
(q, 8.0) 
7.57-7.66 
(m) 
4.95 
(m) 
- 
8.51(syn) (s) 
8.88 (anti) 
(s) 
4.22 (syn) 
(q, 8.0) 
4.31 (anti) 
(q, 8.0) 
1.48 (syn) 
(t, 8.0) 
1.58 (anti) 
(t, 8.0) 
 
Table 2.2. 195Pt and 1H NMR sifts for the [PtN3L]
2+ complexes. 
Table 2.2. 195Pt and 1H NMR shifts for the [PtN3L]
2+ complexes. 
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Attempted Synthesis of [Au(N3)L]
3+ N-heterocycle-complexes. 
The analogous [Au(N3)L]
3+ complexes could not be isolated as stable solids from the reactions 
of AuL1 and AuL2 with the same N-heterocycles in DMF as solvent and the black products 
suggested decomposition. The reactions of AuL1 and AuL2 with dmap and 9-EtGua, respectively, 
were therefore monitored by 1H NMR spectroscopy, in dmf-d7 solution at room temperature, to 
probe the formation of the desired products. While chemical shifts indicative of Au-9-EtGua and 
Au-dmap binding were observed, multiple peaks corresponding to likely decomposition or 
dissociation of the chelate rings were observed over time. The purine and substituted pyridine 
ligands do remain bound even in evidence of chelate ring dissociation - the strength of the Au-
N(dmap) bond has been noted previously.31  
Figure 2.6. 1H NMR (300 MHz) spectra of PtL1a and PtL2a at 20 and 60°C. 
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Reactivity with Biomolecules. 
The structure of the HIV NCp7 peptide is shown in Scheme 2.2. In general, two aspects are 
important – the recognition interaction with tryptophan and the reactivity of the [MCl(N3)] and 
[M(N3)L] species toward cysteine attack. In both cases, we have used extensively the C-terminal 
finger (red box) as it contains the essential tryptophan residue and is a good prognosticator of the 
interaction with the full 2-finger peptide. We also compared reactivity toward the simple amino-
acid N-AcetylCysteine (N-AcCys). 
 
 
Pt(N3)L 𝛑-𝛑 stacking interaction - Tryptophan Quenching Assay. 
In earlier studies we have shown that Pt2+ and Au3+-dmap containing complexes exhibit good 
affinity for N-AcTrp and the NCp7 ZF2 peptide.18,19 For the diethylenetriamine (dien) derivatives, 
[Au(dien)(dmap)]3+ and [Pt(dien)(dmap)]2+ the Ka values are about 3.6 times larger than those for 
the 9-EtGua-containing analogue [Pt(dien)(9-EtGua)]2+ and almost 8 times larger than the Ka for 
the free dmap ligand itself. The Ka values for the [Pt(N3)L]
2+ complexes described in this study 
are consistent with previous trends and confirm that the dmap containing compounds (PtL1a and 
PtL2a) are good tryptophan quenchers (Table 2.3). The Ka values for these complexes are 2 to 3 
times larger than those for complexes containing the N-heterocycles 4-pic (PtL2b) or 9-EtGua 
(PtL2c). Tryptophan affinity for PtL1a
 
containing the Mebpma tridentate ligand is somewhat 
greater than for the bpma containing analogue PtL2a and for the earlier reported Pt(II) and Au(III)-
Scheme 2.2. Structure of the HIV NCp7 peptide. 
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dien complexes, with the exception of [Au(N-Medien)(dmap)]3+.18,19 Coordination to the 
platinum(II) ion increases about 10 times the association constant when compared with the results 
for the free dmap ligands increasing in the following order [Pt(dien)(dmap)]2+< PtL2a < PtL1a. 
Tryptophan quenching in the zinc finger ZF2 also follows this trend and the complex PtL1a 
represents a significant increase over the first-published [Pt(dien)(9-EtGua)]2+.14 For PtL1a, the 
value for interaction with the full NCp7 (residues 1-55) is slightly higher again, Ka = (40.6 ± 1.0) 
x 103 M-1, validating the use of the C-terminal ZF2 as a general indicator of quenching efficacy.  
The electronic delocalization of the dmap π electrons and ligand basicity may be responsible for 
its advantage over 9-EtGua, modifying the HOMO-LUMO gap which has been considered a major 
predictor of stacking affinity.17  
Compound  Ka (x103) M-1  
N-AcTrp  ZF2  
PtL1a  32.8 ± 2.0 33.1 ± 3.7 (40.6 ± 1.0)* 
PtL2a  28.3 ± 3.4 30.7 ± 4.6 
PtL2b  13.4 ± 2.6 17.4 ± 4.7 
PtL2c  11.7 ± 0.7 15.9 ± 1.5 
[Pt(dien)(dmap)] 2+ 25.0 ± 0.9a 28.1 ± 1.8a 
[Au(dien)(dmap)] 3+ 25.5 ± 0.3a - 
[Pt(dien)(9-EtGua)] 2+  6.88 ± 0.3a 7.5a 
dmap 3.19 ± 0.01b - 
References: a18 and b15. *Values in parentheses were obtained with the full NCp7. 
 
 
 
Table 2.3. Association constants for N-heterocycle compounds with the N-AcTrp and NCp7 
ZF2. 
64 
 
Studies of the reactivity of platinum(II) complexes with N-acetylcysteine. 
The covalent interaction with zinc fingers is considered to occur through electrophilic attack 
on the ZF cysteine residues. To examine the reactivity pattern, the reactions of the precursors PtL1 
and PtL2 and of [Pt(N3)L]Cl2
  (PtL1a, PtL2a and PtL2c) with 4 molar equiv. of N-AcCys in D2O 
were first monitored by 1H and 195Pt NMR spectroscopy. The reactions of the substitution-labile 
precursors PtL1 and PtL2 were complete after 2 h, as shown by the appearance of a new signal in 
the 195Pt NMR spectra of both reactions. The signal due to starting material PtL1, at δ -2331.9, 
was replaced by a signal at δ -2903.2, assigned to the reaction product [Pt(Mebpma)Cys]2+, 
whereas the signal due to PtL2, at δ -2301.8, was replaced by that at δ -2848.3, also in agreement 
with a square planar N3S coordination sphere, and therefore formation of [Pt(bpma)Cys]
2+.35,36 The 
195Pt NMR spectra of both the PtL1 and PtL2 reaction mixtures after 24 h show that the intensity 
of the signal assigned to the PtN3S complex has significantly decreased with the rise of broader 
peaks in the same region suggesting that decomposition or further reaction in the presence of 
excess N-AcCys had taken place. To examine this point further the time course of the reactions 
were followed by 1H NMR spectroscopy.  
The 1H NMR spectra of the two [PtCl(N3)]Cl compounds PtL1 and PtL2 show the same profile. 
The spectral interpretation is complicated somewhat by the presence of excess N-AcCys but the 
aromatic region is informative. The 1H NMR spectra of PtL1 and PtL2 in the aromatic region in 
the presence of N-AcCys over 2, 6 and 24 h are presented in Figure 2.7. For PtL1 at 2 h, the 
spectrum of the reaction mixture shows signals of coordinated Mebpma, which are shifted to 
higher frequencies, δ 7.56 (t, 2H, H5), 7.66 (d, 2H, H3), 8.15 (t, 2H, H4), 9.11 (d, 2H, H6) in 
comparison with those in both the free and coordinated Mebpma thus suggesting formation of the 
product [Pt(Mebpma)Cys]+.  The characteristic “pair” of doublets of the H7 protons is obscured 
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somewhat by solvent but the downfield doublet diminishes in intensity and appears as a virtual 
triplet (Figure 2.8). Over time a new set of signals arises with concomitant decrease of the initial 
product peaks. The bulkier S-thiolate ligand could cause steric hindrance and the multiple signals 
arising over time, along with the broadening of the PtNMR signals, could arise from the presence 
of mixtures or isomers of [PtN3(Cys)]
+. The related compound [PtCl(di-6-methyl-2-
picolyl)amine]+ (with a Me group in the C6 position of the N3 ligand , See Scheme 1) undergoes 
relatively facile chelate ring opening in the presence of excess 9-EtGua to produce bisubstituted 
bis(9-EtGua) products.37 Similar ring opening could be expected under the strong trans influence 
of the thiolate ligand.  The final product signals and an accompanying singlet at δ 4.31 are most 
compatible with assignment to free ligand – the shifts are slightly different due to protonation in 
the more acidic environment created by excess of N-AcCys (data not shown). The reaction of PtL2 
occurs more quickly than for the Mebpma derivative. After 24 h the spectrum of the non-
methylated complex PtL2 reaction mixture presents signals assigned to only one aromatic species 
and also attributed to free ligand (Figure 2.7). 
 
Figure 2.7. 1H NMR (400 MHz) spectra in the aromatic region for reactivity assay of 
PtL1 and PtL2 with N-AcCys. Hydrogens marked with a * are assigned to [Pt(N3)(N-
AcCys)]+ complex, and underscores assigned to the protonated free ligand. 
66 
 
 
Mass Spectrometry. 
The ESI-MS spectra of 1:1 reactions are clean and consistent with the interpretation of the 
initial NMR spectra. For PtL1 immediately upon incubation with one equivalent of N-AcCys (t = 
0) the MS showed the major species of starting material (Figure 2.9B) whereas after 24 h this gives 
way to a peak at m/z = 570.11 consistent with [Pt(Mebpma)(N-AcCys)]+ (Figure 2.9D). The 
spectrum of PtL2 immediately upon incubation (Figure 2.9A) shows the presence of starting 
material and also product [Pt(bpma)(N-AcCys)]+ with a very minor peak at m/z =  948.15 
indicative of the μ-cysteine dimer [{Pt(bpma)2}μ-N-AcCys]+ (not shown). Thus, the MS data 
confirm the greater reactivity of PtL2 over PtL1, as seen by NMR spectroscopy. After 24 h the 
dominant peak is that of the mononuclear product (Figure 2.9C). An interesting feature at t = 24 h 
is the presence of [{Pt(bpma)2}μ-N-AcCys]+ and a species at m/z = 1111.18 which corresponds to 
[Pt(bpma)(N-AcCys)]2 (Figure 2.10). Isotopic distribution patterns of products were consistent 
with these assignments in all spectra.  
Figure 2.8. Complete 1H NMR spectra: reactivity assay of PtL1 and PtL2 with N-
AcCys. 
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The reactions of cysteine and glutathione (GSH) with Pt chelate complexes is usually discussed 
in relation to the trans-labilization induced upon formation of the Pt-SR(thiolate) bond and also 
the propensity to form bridged diplatinum μ-thiolate(SR) species.38,39 In the case of cisplatin, 
binding of biologically relevant thiols such as cysteine and glutathione can result in rapid 
dissociation of the Pt-NH3 bond.
36,40 In the case of [PtCl(dien)]+ , dissociation of the dien ligand 
eventually occurs over long periods of time upon reaction with both  cysteine and glutathione.39 
The results discussed here suggest that the bpma and Mebpma ligands are more susceptible to 
ligand dissociation and trans labilization than the ‘aliphatic” dien ligand. The dinuclear 
[{Pt(dien)}2μ-GS]3+ species has been observed in a rapid reaction of [Pt(dien)(GS)]+ with a second 
[PtCl(dien)]+ unit.38 However, the peak assignable to formation of the μ-Cys dinuclear species for 
PtL1 is of very minor intensity, suggesting that the increased “in-plane” steric demands of the 
bpma and Mebpma ligands27 do not favor the approach of a second Pt unit to the first formed 
[Pt(bpma/Mebpma)(N-AcCys)]+ species.    
Gold Complexes. 
The reactions of AuL1 and AuL2 with N-AcCys immediately produce white precipitates (data 
not shown).  This behavior is identical to that observed for [AuCl(dien)]2+ and also 
[Au(dien)(dmap)]3+.31 The thiol-containing amino acid L-cysteine quickly reduces Au3+ in 
aqueous solution, the reaction being complete in the first minute.22,41,42 The initial rapid 
substitution reaction results in an unstable Au(III)-S complex that is reduced to Au1+/Au0 in a 
slower electron-transfer process.22,41 
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Figure 2.9. MS spectra of 1:1 reaction between N-AcCys and (A) PtL2 immediately; (B) 
PtL1 immediately; (C) PtL2 after 24 h; (D) PtL1 after 24 h. 
 
Figure 2.10. Expanded MS spectrum of 1:1 reaction between N-AcCys and 
[PtCl(bpma)]Cl (PtL2) after 24 h. 
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Formally substitution-inert [Pt(N3)L]
2+ complexes. 
In contrast with the results discussed above for the substitution-labile [PtCl(N3)]
+ complexes 
PtL1 and PtL2, the 1H and 195Pt NMR spectra obtained after mixing the [Pt(N3)L]Cl2 (PtL1a, PtL2a 
and PtL2c) compounds with N-AcCys in 1:1 stoichiometric ratios do not show any change, even 
after 72 h of incubation (Figure 2.11). When 1:4 {Pt:N-AcCys} stoichiometry is used in the 
reaction of PtL1a, peaks of very low intensity appear after 24-72 h at δ = -2850-2900 ppm 
indicating some formation of PtN3S species. These results confirm the inertness of the 
[Pt(N3)L]Cl2 compounds in the presence of the sulfur-containing amino acid N-AcCys. In 
principle, the advantage of a substitution-inert system, such as [Pt(N3)L]
2+ complexes in general, 
as an in vivo NCp7 inhibitors, is that they would not be easily “deactivated” by other sulfur-
containing biomolecules. In this context, efforts towards tuning these complexes is essential, so as 
to favor reactions with strong nucleophiles, such as ZF cysteine residue thiol groups, as suggested 
previously.19 
 
 
Figure 2.11. 1H NMR spectra: reactivity assay of PtL1a with N-AcCys. 
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Studies of the reactivity of complexes PtL1, AuL1 and PtL1a with the C-terminal finger of HIV 
NCp7, ZF2. 
The interactions between the [MCl(N3)]
n+ (PtL1 and AuL1) and [Pt(N3)L]
2+ (PtL1a) complexes 
with the C-terminal finger of the HIC NCp7 peptide (ZF2) have been monitored by mass 
spectrometry. Immediate interaction between PtL1 and ZF2 results in complete loss of the Zn2+ 
ion and Mebpma ligand (Figure 2.12A). The mass spectrum shows an intense peak at m/z of 371.50 
assigned to the apoprotein [apoF]6+ and minor peaks at m/z of 445.40 [apoF]5+ and 556.49 
[apoF]4+. The peak at m/z of 484.39 corresponding to [PtF]5+ proves that PtL1 was able to eject 
the Zn2+ ion of the ZF2 domain, forming a 1:1 [Pt:F] adduct. To our knowledge this is the first 
observation of the “simple” {PtF} species. After 24 h the spectra show adducts corresponding to 
species with multiple Pt units [(PtL)-PtF]n+ perhaps from gas-phase interaction of PtL1 with the 
initially pre-formed PtF (Figure 2.12B). The results contrast to those previously shown for 
[PtCl(dien)]+ where the dien ligand is retained in the initial stages of the reaction producing species 
such as Pt(dien)-ZF or Pt(dien)-F and no {PtF} species was observed.14,42 In contrast, the MS 
spectrum obtained after incubation with [PtCl(dien)]Cl for 15 h (Figure 2.13), still shows the 
presence of unoxidized ZF as the major product, at m/z of 762.31 (ZF3+) and 1144.46 (ZF2+), and 
only a small peak corresponding to Pt(dien)-ZF3+ is observed at m/z of 862.33, which is very 
similar to previous MS results for this complex.43 The results overall are broadly consistent with 
the model NAcCys case discussed above. The greater reactivity of the Mebpma complex could be 
related to its electron-withdrawing properties, due to the π-back bonding of the pyridine nitrogens, 
responsible for its lesser basicity compared with dien.27 The same trend was observed previously 
for the [MCl(dien)]n+ and [MCl(terpy)]n+ complexes.43 
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Indeed, the behavior of {Pt(Mebpma)} species with total loss of ligand in the initial reaction 
is more reminiscent of the general Au(III) behavior we observed here and previously.31,43 The MS 
spectra of the AuL1 and ZF2 mixture indicate immediate reaction with peptide oxidation and 
ejection of the Zn2+ ion (Figure 2.12C). As seen before for other gold(III) complexes,31,43 Zn2+ 
ejection and AuxF
n+ formation occurs immediately, with peaks assigned to [Au2F]
5+ (m/z = 
523.78), [AuF]4+ (m/z = 604.98), [Au2F]
4+ (m/z = 654.48), [AuF]3+ (m/z = 806.64), [Au2F]
3+ (m/z 
= 872.30) and [Au4F]
3+ (m/z = 1003.61). Peaks corresponding to the oxidized apoprotein are also 
seen at m/z of 445.00 [apoF5+], 555.99 [apoF4+] and 741.33 [apoF3+]. Careful examination of the 
spectra show low intensity companion peaks of, for example, the apoF4+ species corresponding to 
the presence of an extra 1, 2, or 3 oxygen atoms suggesting higher-order oxidized sulfur species 
(Figure 2.14). The rapid reaction of AuL1 (and also [AuCl(dien)]2+) to form “gold fingers” is in 
accordance with the greater reactivity of gold(III) compared with platinum(II) complexes.  
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Figure 2.12. MS spectra of 1:1 reaction between NCp7 ZF2 of (A) PtL1 immediately; (B) 
PtL1 after 24 h; (C) AuL1 immediately. 
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Figure 2.13. MS spectrum of the 1:1 mixture of [PtCl(dien)]Cl with 
ZF2 after 15h. 
 
Figure 2.14. Expanded version of ESI-MS spectrum of the product of 
[Au(Mebpma)Cl]2+ and C-terminal ZF2 showing the apoF4+ ion and the 
presence of associated oxidized -SO, -SO2 and -SO3 adducts of the 
apopeptide. 
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Substitution-inert [Pt(N3)L]
2+ Complexes. 
For the incubation of the dmap-containing complex PtL1a with ZF2, which contains a fourth 
nitrogen coordinated to the metallic ion, the mass spectrum (Figure 2.15) confirms the non-
covalent interaction, as can be observed by the weak peaks assigned to the 1:1 adduct (PtL1a:ZF) 
at m/z of 939.70 (PtL1a -ZF3+) (not shown), 1408.04 (PtL1a -ZF2+) and 1427.53 (K+ PtL1a-ZF2+). 
It is noteworthy that even for a weak non-covalent interaction these peaks can be observed in the 
ESI-MS spectrum under the appropriate conditions. No change is observed over time. 
 
 
2.4 Conclusions 
The reactions of {MClN3} species [PtCl(Mebpma)]Cl (PtL1) and [AuCl(Mebpma)](PF6)2 
(AuL1) complexes and the analogous bpma complexes (PtL2 and AuL2) with N-AcCys and NCp7 
ZF2 have been investigated. Comparison of the 1H NMR data suggest appreciable withdrawal of 
electron density from the N3 ligand, which is more pronounced in the gold(III) complexes than in 
Figure 2.15. MS spectrum of the 1:1 mixture of [PtL1a]Cl2 with the C-terminal zinc finger 
of HIV NCp7. The expansion of noncovalent adduct peak and the theoretical m/z are shown 
in the right. 
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the platinum(II) analogues, and explains the facile deprotonation of AuL2 and the relative 
instability of both gold(III) complexes, also associated with the ease of Au3+ reduction in both 
cases.25 Indeed, only the platinum(II) N-heterocyclic compounds of the type [Pt(N3)L]Cl2
 could be 
isolated in their pure form from the reactions of the precursors PtL1 and PtL2 with 4-
dimethylaminopyridine (dmap), 9-ethylguanine (9-EtGua) and 4-methylpyridine (4-pic). 
Formation of the analogous [Au(N3)L]
3+ complexes occurs in solution and can be monitored by 
1H NMR Spectroscopy but no stable solid products were isolated.  
As shown by the reactivity assay, the [Pt(N3)L]
2+
 complexes are inert and react only very 
slowly with excess N-AcCys. In contrast, the [PtCl(N3)]
+ complexes PtL1 and PtL2 react with N-
AcCys almost immediately to yield substitution products [Pt(N3)Cys]
2+, which seem to undergo 
decomposition with release of the chelate ligand after 24 h. The decomposition of the bpma 
containing species is faster than that for Mebpma. These results are consistent with the ESI-MS 
spectrometry results with the zinc finger which shows adducts M:F (apopeptide) adducts for PtL1 
similar to that found for AuL1. For both complexes the reactions with ZF2 occur with Zn
2+ ejection, 
which is not seen for the [PtCl(dien)]+ analogue. The reaction with AuL1 occurs quickly, as seen 
before for other gold(III) complexes, resulting in “gold fingers” and oxidized apoF peptide. These 
results suggest a greater deactivation/inhibition action of the NCp7 ZF2 by the Mebpma-
containing complexes, especially for AuL1. 
Interaction of the inert [Pt(N3)L]
2+ complexes with Trp was investigated and the results show 
that the presence of the dmap ligand results in complexes with considerable affinity for the amino 
acid. Furthermore, PtL1a is one of the best Trp fluorescence quenchers among the complexes 
reported herein and previously studied platinum(II) and gold(III) analogues both for the free 
amino-acid and the NCp7 peptide sequence. The association constant determined with the full 
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NCp7 peptide is significantly higher than that found for [Pt(dien)(9-EtGua)]2+ (Ka = 20 x 10
-3 M-1 
) and comparable to values found for organic inhibitors of the HIVNCp7-RNA interaction.44 The 
association constant with the C-terminal finger is sufficiently strong that formation of the non-
covalent PtL1a:ZF2 adduct may be confirmed by ESI-MS without Zn2+ ejection. In summary, it 
was possible to improve the non-covalent π-π stacking interaction of [Pt(N3)L]2+ complexes with 
Trp by tuning the ligands coordinated to the platinum(II) ion, with the potential for selective 
interaction with the HIV-NCp7 protein.  
The results are overall consistent with a greater reactivity of bpma over dien chelate. The 
relative displacement of Cl- from [PtClN3]
+ (where N3 = terpyridine, bpma and dien) by isosteric 
pyridine nucleophiles has been discussed in terms of the reactivity and discrimination ability of 
the {PtN3} reaction centre.
26 The reactivity is linearly related to the basicity of the isosteric 
entering nucleophiles and the ability of the substrates to discriminate among neutral nucleophiles 
of different basicity was considered a measure of their relative electrophilicity terpy > bpma > 
dien. Broadly, the results presented here and comparison with the previously studied 
[PtCl(terpy)]+,
 42 extrapolate these findings to biologically relevant thiols and thiol-containing 
peptides.  Indeed, bpma represents an intermediate case between terpy and dien. In this respect is 
noteworthy that a peak at 311.0 m/z in the spectrum of AuL1 and the ZF2 may represent 
{Zn(Mebpma)Cl}(Figure 2.12) with chelate transfer as observed previously with the terpy 
analog.43 Both the electronic structure and steric demands in going from sp2 planar (terpy) to 
sp2/sp
3 (bpma) to all sp3 (dien) nitrogens may contribute to the kinetic differentiation as 
suggested.25 Once again, these results indicate that it is possible to design new candidates to 
interact more selectively with biomolecules. The inertia of the [Pt(N3)L]
2+
 complexes could be 
useful in the search for more selective NCp7 inhibitors, once those complexes can react favorably 
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with strong nucleophilic amino acids residues as ZF Cys residues, avoiding “deactivation” 
reactions with other biomolecules (sulfur-containing Cys residues). The syntheses of novel 
complexes containing different N-donor ligands that are able to form relatively stable complexes 
with NCp7 or that lead to Zn2+ ejection are also under further investigation. 
2.5 Experimental Section 
Materials and methods. 
[PtCl(dien)]Cl,29 [AuCl(dien)]Cl2,
30 [AuCl(bpma)](OTf)2,
25 and bis(2-
pyridylmethyl)methylamine (Mebpma)45 were synthesized according to the literature. All reagents 
used in this study were analytical grade and used without further purification. N-acetyltryptophan 
(N-AcTrp), N-acetylcysteine (N-AcCys), bis(2-pyridylmethyl)amine (bpma), 4-
dimethylaminopyridine (dmap), 9-ethylguanine (9-EtGua) and 4-methylpyridine (4-pic), were 
purchased from Sigma Aldrich. Apo-peptides were purchased from GenScript Corporation and 
had the following sequences: NCp7 ZF2 (KGCWKCGKEGHQMKDCTER), and the full NCp7 
(MQRGNFRNQRKNVKCFNCGKEGHTARNCRAPRKKGCWKCGKEGHQMKDCTERQAN
). The zinc finger peptides were prepared according to our published procedures14,43 and 
characterized by CD and mass spectrometry. 
Synthesis.   
[PtCl(Mebpma)]Cl (PtL1). cis-[PtCl2(DMSO)2] was stirred for 24 h in 20.0 mL of CH2Cl2 with 
1.1 equiv. of Mebpma in the dark. The yellow solid was washed with CH2Cl2 and diethyl ether 
and dried in vacuo (60% yield). Anal. Calcd. (%) for C13H15Cl2N3Pt(H2O)1.5: C, 30.84; H, 3.58; 
N, 8.30. Found: C, 29.41; H, 3.13; N, 7.54.  1H NMR (D2O, 400 MHz): δ 3.05(s, 3H), 4.60 (d, J = 
16.0 Hz, 2H), 5.17 (d, J = 12.0 Hz, 2H), 7,51 (t, J = 8.0 Hz, 2H), 7,65 (d, J = 8.0 Hz, 2H), 8.14 (t, 
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J = 8.0 and 4.0 Hz, 2H), 8.76 (d, J = 4.0 Hz, 2H). 195Pt NMR (85.80 MHz, D2O, δ/ppm): -2331.9. 
IR (KBr, selected peaks)/cm–1: ν(PtCl) 377, ν(PtN) 441, 485. 
[PtCl(bpma)]Cl (PtL2). Synthesized as described for PtL1, except for the use of 1.1 equiv. of 
bpma. The suspension was filtered and the light grey solid, washed with CH2Cl2 and diethyl ether 
and dried in vacuo (98% yield). Anal. Calcd. (%) for C12H13Cl2N3Pt: C, 30.98; H, 2.82; N, 9.03. 
Found: C, 30.77; H, 2.57; N, 8.79. 1H NMR (D2O, 400 MHz): δ 4.65 (d, J = 16.0 Hz, 2H), 4.96 
(d, J = 16.0 Hz, 2H), 7.21 (t, J = 8.0 Hz, 2H), 7.52 (d, J = 8 Hz, 2H), 7.98 (td, J = 8.0 and 4.0 Hz, 
2H), 8.53 (d, J = 4.0 Hz, 2H). 195Pt NMR (85.80 MHz, D2O, δ/ppm): -2301.8. IR (KBr, selected 
peaks)/cm–1: ν(PtCl) 322, ν(PtN) 449, 491.  
[Pt(Mebpma)(dmap)]Cl2 (PtL1a). PtL1 was stirred in the dark under reflux for 5 h in 15.0 mL 
of distilled water with 1 equiv. of dmap. The solution was stirred at room temperature for an 
additional 19 h. The solvent was evaporated to near dryness and 20.0 mL of acetone were added 
and the mixture, stirred for 30 min. The suspension was filtered and the brownish solid, washed 
with acetone and diethyl ether and dried in vacuo (47% yield). Anal. Calcd. (%) for 
C20H25Cl2N5Pt(H2O)5: C, 34.74; H, 5.10; N, 10.13. Found: 34.12; H, 4.84; N, 9.78. 
1H NMR (D2O, 
400 MHz): δ 3.06 (s, 3H), 3.15 (s, 6H), 4.66 (d, J = 16.0 Hz, 2H), 5.17 (d, J = 16.0 Hz, 2H), 6.84 
(br s, 2H), 7.43 (t, J = 8.0 Hz, 2H), 7.73 (m, 4H), 8.18 (td, J = 8.0 and 4.0 Hz, 2H), 8.38 (br s, 2H). 
195Pt NMR (85.80 MHz, D2O, δ/ppm): -2413.1. IR (KBr, selected peaks)/cm–1: ν(PtN) 446, 489. 
[Pt(bpma)(dmap)]Cl2 (PtL2a). Synthesized as described for PtL1a starting with PtL2, and 
obtained as a white solid (87% yield). Anal. Calcd. (%) for C19H23Cl2N5Pt(H2O)5: C, 33.68; H, 
4.91; N, 10.34. Found: C, 32.82; H, 4.77; N, 9.88. 1H NMR (D2O, 400 MHz): δ 3.15 (s, 6H), 
overlapped (4H), 6.85 (br s, 2H), 7.37 (t, J = 8.0 Hz, 2H), 7.67 (m, 4H), 8.13 (td, J = 8.0 and 4.0 
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Hz, 2H), 8.46 (br s, 2H). 195Pt NMR (85.80 MHz, D2O, δ/ppm): -2401.5. IR (KBr, selected 
peaks)/cm–1: ν(PtN) 450, 496, 526. 
[Pt(bpma)(4-pic)]Cl2 (PtL2b). Synthesized as described for PtL2a except for the use of 1.15 
equiv. of 4-pic, and obtained as a white solid (83% yield). Anal. Calcd. (%) for 
C18H20Cl2N4Pt(H2O)2.5: C, 35.83; H, 4.18; N, 9.29. Found: C, 34.38; H, 3.74; N, 8.88. 
1H NMR 
(D2O, 400 MHz): δ 2.58 (s, 3H), overlapped (m, 4H), 7.35 (t, J = 8.0 Hz, 2H), 7.56 (d, J = 4.0 Hz, 
2H), 7.67 (d, J = 8.0 Hz, 2H), 7.67 (br s, 2H), 8.15 (td, J = 8.0 and 4.0 Hz, 2H), 8.92 (br s, 2H). 
195Pt NMR (85.80 MHz, D2O, δ/ppm): -2405.5. IR (KBr, selected peaks)/cm–1: ν(PtN) 449, 494. 
[Pt(bpma)(9-EtGua)]Cl2 (PtL2c). Synthesized as described for PtL2a except for the use of 1.15 
equiv. of 9-EtGua and obtained as a light yellow solid (93% yield). Anal. Calcd. (%) for 
C19H22Cl2N8OPt(H2O)3.5: C, 32.26; H, 4.13; N, 15.84. Found: C, 31.58; H, 4.10; N, 15.37. 
1H 
NMR (D2O, 400 MHz): δ 1.48 (syn) and 1.58 (anti) (t, J = 8.0 Hz, 3H), 4.22 (syn) and 4.31 (anti) 
(q, J = 8.0 Hz, 2H), 4.95(m, 4H), 7.33 (q, J = 8.0 Hz, 2H), 7.57-7.66 (m, 4H), 8.12 (t, J = 8.0 Hz, 
2H), 8.51 (syn) and 8.88 (anti) (s, 1H). 195Pt NMR (85.80 MHz, D2O, δ/ppm): -2362.7; -2379.0. 
IR (KBr, selected peaks)/cm–1: ν(PtN) 447, 491. 
 [AuCl(Mebpma)](PF6)2 (AuL1) Synthesized analogously to [Au(bpma)Cl](PF6).  To a stirring 
solution of tetrachloroauric acid was added 1 equiv. of Mebpma in the presence of 2 equiv. of 
ammonium hexafluorophosphate.  The tan precipitate isolated by filtration and washed with water 
(53.5% yield). Anal. Calcd (%) for [(C13H15N3)AuCl](PF6)2: C, 21.23; H, 2.06; N, 5.71.  Found: 
C, 21.29; H, 1.59; N, 5.93.  1H NMR (DMF-d7, 300 MHz): δ 3.94 (s, 3H), 5.47 (d, 2H), 6.35 (d, 
2H), 8.13 (t, 2H), 8.31 (d, 2H), 8.72 (t, 2H), 9.13 (d, 2H). 
[AuCl(bpma-H)](PF6) (Au(L2-H))  [Au(bpma-H)Cl](PF6) was synthesized by addition of 1 
equiv. of BPMA to a solution of tetrachloroauric acid in water in the presence of 1 equiv. of 
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ammonium hexafluorophosphate.  The red precipitate was filtered and washed with water (70.7% 
yield).  Anal. Calcd. (%) for [Au(C12H12N3)Cl](PF6): C, 25.04; H, 2.10; N, 7.30.  Found: C, 24.91; 
H, 1.87; N, 7.14.  1H NMR (DMF-d7, 300 MHz): δ 4.40 (s, 4H), 7.96 (m, 2H), 8.21 (d, 2H), 8.55 
(m, 2H), 9.14 (d, 2H).  
NMR experiments. 
1H and 195Pt NMR spectra were recorded on a Bruker AVANCE III 400 MHz spectrometer. 
1H NMR are reported with reference to solvent resonances of D2O at δ 4.79 – the dmf-d7 spectral 
shifts were adjusted appropriately. The 195Pt{1H} NMR spectra including those of the N-AcCys 
assay were obtained in D2O, at room temperature, with 40 mM solutions, at an operating frequency 
of 85.80 MHz, range of -1900 to -3500 ppm and 5000 scans. The spectra were referenced 
externally using standards of Na2PtCl6 in D2O (δ = 0 ppm). The 1H NMR spectra of the 4-pic and 
dmap platinum complexes were recorded on a Varian Mercury-300 MHz, at 293 and 333 K (60ºC). 
The samples were prepared in D2O, at 20 mM approximate concentration and the spectra, obtained 
with an average number of 32 scans.  
Fluorescence spectroscopy. 
Fluorescence studies were recorded on a Varian Cary Eclipse fluorometer. Solutions of the 
[Pt(N3)L]Cl2 species were prepared in water to a final concentration of 1.5 mM. 1 mM stock 
solutions of N-AcTrp, ZF2 and NCp7 were prepared in 20 mM tris buffer with 50 mM NaCl at pH 
7.4. In a fluorescence cuvette, 3 mL of a 5 μM solution of N-AcTrp, ZF2 and NCp7 was titrated 
with volumes of 10 μL of the stock solution of the platinum(II) compounds at molar ratios from 1 
to 10, and the fluorescence emission was measured in a 300-450 nm range, with an excitation 
wavelength of 280 nm and a detector voltage of 700 V for N-AcTrp and 750 V for ZF2 and NCp7 
at room temperature.  The emission maximum (360 nm) was measured after each titration. The Ka 
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values were determined from Eadie-Hofstee plots and were determined from an average of 3 trials 
using the following equation: ΔF = (Ka)−1ΔF/[quencher] + ΔFc. 
Mass Spectrometry. 
For the electrospray ionization mass spectrometry experiments, 1:1 mixtures of PtL1a:ZF2 
was prepared. The samples were sprayed immediately using a final concentration of ~100 μM. 
Experiments were carried out on an Orbitrap Velos from Thermo Electron Corporation operating 
in positive mode. Samples were diluted with methanol and directly infused at a flow rate of 0.7 
μL/min using a source voltage of 2.30 kV. The source temperature was maintained at 230°C 
throughout. MCl(N3) complexes were incubated with N-AcCys or NCp7 ZF2 at 1: 1 molar ratios, 
and the reaction mixtures at t = 0 and 24 hours were monitored by ESI-MS under the same 
conditions. 
Far infrared-(FIR) Spectroscopy. 
Far Infrared (FIR) Fourier Spectra were obtained in KBr pellets in a Nicolet – Nexus 670 FT-
IR in the 600–200 cm-1 frequency range, with an average number of 32 scans. 
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2.7 Appendix 
 
Figure 2.16. Interaction of [Au(BPMA)Cl]+ with one equivalent of DMAP monitored by 1H-
NMR for 10 hours. 
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Figure 2.17. Interaction of [Au(Me-BPMA)Cl]2+ with one equivalent of DMAP monitored 
by 1H-NMR for 10 hours. 
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Chapter 3: Investigation of 1-Methylcytosine as a 
Ligand in Gold(III) Complexes: Synthesis and 
Protein Interactions 
James Beaton 1 and Nicholas P. Farrell 1,* 
1Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia 23284-
2006, United States 
3.1 Abstract 
The HIV nucleocapsid protein NCp7 has been previously shown to play a number of roles in 
the viral life cycle, and has previously been identified as a potential target for small molecule 
intervention. In this work, the synthesis of the previously unreported complexes 
[Au(dien)(1MeCyt)]3+, [Au(N-Medien)(1MeCyt)]3+, and [Au(dien)(Cyt)]3+ is detailed, and the 
interactions of these complexes with models for NCp7 are described. The affinity for these 
complexes with the target interaction site, the “essential” tryptophan of the C-terminal zinc finger 
motif of NCp7, was investigated through the use of a fluorescence quenching assay and by 1H-
NMR spectroscopy. The association of [Au(dien)(1MeCyt)]3+ as determined through fluorescence 
quenching is intermediate between the previously reported DMAP and 9-EtGua analogs, while the 
associations of [Au(N-Medien)(1MeCyt)]3+ and [Au(dien)(Cyt)]3+ are lower than the previously 
reported complexes. Additionally, NMR investigation of this interaction shows that the association 
of complexes of this nature may be weaker than previously reported. The specifics of the 
interaction with the C-terminal zinc finger were investigated by circular dichroism spectroscopy 
92 
 
and electrospray-ionization mass spectrometry. The interaction is complete nearly immediately 
upon mixing, and the formation of AuxF
n+ (x = 1, 2, or 4; F = apopeptide) concomitant with the 
loss of all ligands was observed. Additionally, for the first time oxidized dimerized peptide was 
observed as a product, indicating reaction via a charge transfer mechanism. 
3.2. Introduction 
Gold compounds have a long history in medicinal chemistry. The thiophilic nature of gold 
suggests sulfur-rich proteins such as thioredoxin as reasonable cellular targets for gold action.1 
Au(III) is quite labile in its chemistry and susceptible to reduction to Au(I).1 Apart from the 
inherent difficulty in understanding speciation of a Au(III) complex in a biological medium, non-
selective interactions are also highly likely. This is especially true when highly nucleophilic sulfur 
sites in proteins are considered as viable targets. Formally substitution-inert coordination spheres 
such as MN4 or MN3L (where M = Pt, Au and N4 may be an N3 chelate such as diethylenetriamine 
(dien) and L a purine or pyrimidine ligand) have been explored by our group for greater specificity 
with biomolecules.2 In principle, we have suggested that highly nucleophilic cysteines of 
biomolecules can be targeted using weak nucleophiles such as Platinum-Nucleobase PtN4 
Complexes for selective peptide reactions. While Au(III) is chemically more reactive than Pt(II) 
the same principle applies. A complementary approach to enhance selectivity in metal ion-
biomolecule interactions is to use an inherent property of the protein along with appropriate design 
of the small molecule. A two-stage approach to selectivity can then be envisaged – molecular 
recognition followed by “fixation” where the inorganic moiety forms covalent linkages to the 
protein of interest. In this contribution we summarize how this approach might work using 
formally substitution-inert gold-metal nucleobase complexes and a tryptophan-containing zinc 
finger peptide from the HIV nucleocapsid protein HIVNCp7. Specifically, we describe the 
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synthesis and properties of Au(III)-1-MeCytosine complexes and their interactions with the C-
terminal NCp7-F2 targeting the essential tryptophan of the protein.  
Zinc binding proteins are one of the most common types of metalloprotein, and make up as 
much as 10% of proteins found in humans.3 In these proteins, zinc can serve a catalytic role, a 
structural role, and even a recently discovered inhibitory role.4,5 In zinc finger proteins, the zinc 
serves a structural role binding in a tetrahedral geometry to four surrounding amino acids.6 These 
amino acids are generally a combination of cysteines and histidines, and take the forms Cys2His2, 
Cys2HisCys (Cys3His), or Cys4, and modification of the zinc-coordinating residues can have a 
dramatic effect on protein function.7 The HIV nucleocapsid protein (NCp7), a 55 amino acid 
protein that contains two Cys3His zinc fingers (Figure 3.1), has been identified as a potential target 
for chemical intervention through the modification of these structural elements, and it has been 
previously shown that alteration of the zinc coordination sphere significantly hinders viral 
replication.4 NCp7 interacts with its polynucleotide substrate, viral RNA, through guanine stacking 
with both W37 on the second C-terminal zinc finger motif, as well as through the phenylalanine 
(F16) located on the first zinc finger.4,8 
NCp7 recognition by small molecules can be optimized through a noncovalent π-π stacking 
interaction between the “essential” tryptophan residue and metallated nucleobases, analogous to 
the RNA(DNA) interaction. Previously reported gold (III) complexes based on [Au(dien)L]3+ 
(dien = diethylenetriamine; L = N-heterocycle) have been investigated for their ability to stabilize 
the Au(III) oxidation state, as well as their ability to eject zinc from zinc finger proteins.9-12 In the 
case of coordination complexes, this interaction brings the metal center in close contact with the 
highly nucleophilic zinc bound cysteine residues, allowing for secondary electrophilic attack by 
the metal center, resulting in zinc ejection.2,9 Changing the N-heterocyclic ligand can be used to 
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fine-tune the electronic properties of the metal center to impart higher selectivity for the protein of 
interest. To this end, the [Au(dien)L]3+ coordination sphere was studied with the previously 
uninvestigated ligand 1-methylcytosine (1-MeCyt). Compared to the N-heterocycles 4-
Dimethylaminopyridine (DMAP) and 9-Etylguanine (9-EtGua), the free ligand 1-MeCyt has a 
higher association constant with tryptophan.13 Additionally, 1-MeCyt has an intermediate basicity 
(pKa = 4.45) relative to DMAP (pKa = 9.1) and 9-EtGua (pKa(N7) = 2.7).
14 Previously, basicity of 
the heterocycle was thought to be proportional to association constant in the [Au(dien)(N-
heterocycle)]3+ motif.9 The [Au(dien)(1-MeCyt)]3+ is, to our knowledge, the first 1-MeCytosine 
compound of Au(III) to be synthesized and completes the series of Pt(II) and Pd(II) complexes 
[M(dien)L]n+ (L = 9-EtGua, 1-MeCyt) studied for their isostructural and isoelectronic 
similarities.13,15,16 We report the synthesis of the [Au(dien)(1-MeCyt)]3+ (A), [Au(N-Medien)(1-
MeCyt)]3+ (B), and [Au(dien)(Cyt)]3+ (C) (Figure 3.1).  The associative interaction with N-Acetyl-
L-tryptophan (NAcTrp) as a model for the recognition site of NCp7 (W37) was probed through 
the use of a fluorescence quenching assay. Additionally, the interactions with the C-terminal zinc 
finger of NCp7 (Figure 3.1) were investigated by mass spectrometry and circular dichroism 
spectroscopy. 
3.3. Results 
Synthesis and Characterization 
The previously unreported complexes A, B, and C (Figure 3.1) were successfully synthesized 
in accordance with the previously published methods.9 The 1H-NMR spectra of the complexes A 
and of B show multiple protonation states with varying pH* (Figure 3.2), analogous to the 
previously reported 9-EtGua analogs.9 As 1-MeCyt does not have a labile proton, the changes in 
the shifts observed with changing pH may be due to the previously reported deprotonation of the 
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dien chelate, likely at the central nitrogen (pKa = 3.3 for 9-EtGua analog).
9 By analogy with the 
Pd and Pt complexes (see reference 13), the N3 is assigned as the binding site to Au(III). Unique 
to the 1-MeCyt complexes, the signals for the aromatic H6 protons split. This splitting of the 
aromatic protons is not observed in the complex of C nor in the platinated analog, and highlights 
the increased electronegativity of Au(III) relative to Pt(II).16,17  
 
 
 
 
The mass spectra of A and B  are typical of many coordination complexes, in that the parent 
ion peak is nearly indistinguishable from the background but the Au(III)-diethylenetriamine 
Figure 3.1. Structures of the complexes studied. Metal binding sites are highlighted in red. 
Figure 3.2. The 1H-NMR spectra of A (left) and B (right) at varying pH* values, where pH* 
is the reading of the pH meter. 
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backbone bound to fragments of 1-MeCyt is observed, indicating that the desired product had been 
obtained (Figure 3.3). Synthesis of the ribosylated analog of [Au(Dien)(Cyd)]3+ (Cyd = cytidine) 
was attempted, but the recovered yellow product quickly turned purple, indicating the formation 
of colloidal gold (reduction of the metal center to Au(0)).  
 
 
Determination of Tryptophan Affinity by Fluorescence Quenching 
Complexes A, B, and C were titrated into a solution of NAcTrp, and fluorescence quenching 
was used to determine the affinity (Figure 3.4). Complex B shows a lower affinity for NAcTrp (Ka 
= 13.0 × 103 M-1) than the DMAP and 9-EtGua analogs. The association constant for A as 
determined by tryptophan quenching (24.2 × 103 M-1) is intermediate between that of the DMAP 
and 9-EtGua analogs, while C has a lower association constant (9.31 × 103 M-1). The synthesis and 
study completes the isoelectronic and isostructural series [M(dien)L]n+ where M = Pd(II), Pt(II) 
and Au(III) and L = purine, 9-Ethylguanine, or pyrimidine, 1-meCytosine.9,16 Figure 3.4 shows 
how, for this closely related series, the electronic factors from individual metal ions can be 
modulated to control to some extent the tryptophan affinity.13 
Figure 3.3. Mass spectra of A (left) and B (right). 
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Interactions with Zinc Finger Proteins 
Circular dichroism (CD) can be used to gain qualitative information about the structure of the 
zinc finger protein. As previously described, the zinc finger structural motif, as seen in the second 
finger of HIV-NCp7, has a characteristic positive band at 220 nm and a negative band at 195-200 
nm.18 The CD spectrum of the C-terminal zinc finger motif of NCp7 (NCp7-F2) was recorded 
before and after incubation with one equivalent of A, and the interaction was monitored for four 
hours (Figure 3.5). 
Similarly to all previously studied gold(III)-dien complexes, the interaction with A results in 
rapid zinc ejection. The decrease seen in the positive band at 220 nm and the increase seen in the 
negative band at 200 nm upon interaction are indicative of random coil, and are similar to the 
previously reported CD spectrum of the apopeptide.10 Thus, it is assumed that the zinc has been 
ejected very rapidly. Additionally, the spectrum does not change over the remainder of the next 
four hours, indicating that the reaction is complete after 15 minutes. After a 15 minute incubation 
with B, the result was also zinc ejection (data not shown). 
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Figure 3.4. Association constants for [M(dien)(nucleobase)]n+ determined by fluorescence 
quenching of NAcTrp.9,15,16 
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Mass spectra of a 1:1 mixture of NCp7-F2 and A were recorded immediately after mixing, 
after 6 hours, and after 24 hours (Figure 3.6a, 3.7, and 3.8). The spectra did not change substantially 
from the initial timepoint to the final measurement, supporting the results obtained in the CD 
spectra and in the previous literature that the interaction between Au(III) complexes and zinc finger 
peptides occurs rapidly. At the time of the initial measurement, the zinc-coordinated peptide is not 
observed. Additionally, all Au-bound ligands are lost and only the well described “gold fingers” 
are observed.10 Replacement of zinc by one, two, and four atoms of gold was observed: 605.4805 
m/z (4+), 438.1595 m/z (6+), and 1003.2671 m/z (3+) respectively. This is the first instance that 
incorporation of four gold atoms has been observed upon interaction with a single zinc finger 
motif. Oxidized apopeptide (without zinc) is the most readily observable species; 741.3176 m/z 
(3+), 1111.4739 m/z (2+). An unusual feature, not seen previously in our studies, is the presence 
of oxidized dimerized apopeptide assigned to the mass observed at 889.5802 m/z for the n=5 
charge state.   
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Figure 3.5. Circular dichroism spectrum of a 1:1 mixture of the C-terminal Zinc Finger of 
NCp7 and A, monitored over 4 hours. 
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(a) (b) 
Figure 3.6. Mass spectra of a 1:1 mixture of A (a) and B (b) with the C-terminal zinc finger of 
NCp7. 
Figure 3.7. Mass spectrum of A with NCp7-F2 immediately after mixing. 
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Mass spectra of a 1:1 mixture of NCp7-F2 and B taken immediately upon mixing and after one 
hour of incubation show essentially the same products as the spectra observed upon interaction 
with A (Figure 3.6b, Figure 3.9). Additionally, there is little difference in the initial spectrum and 
spectra obtained at later time points, again indicating that the reaction between NCp7-F2 and B is 
very rapid. Oxidized peptide and oxidized dimerized peptide were again seen, as well as 
incorporation of one, two, and four gold ions. Generally, because the ligands are not observed 
attached to gold after interaction with zinc finger proteins, the species observed in the mass spectra 
of the reaction with A and B are identical.  
 
 
Figure 3.8. Mass spectrum of A with NCp7-F2 6 hours after mixing. 
 
Figure 3.9. Mass spectrum of B with NCp7-F2 1 hour after mixing. 
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Cyclic Voltammetry 
CV studies of complexes A and B showed that the new complexes follow the trend of resistance 
towards reduction seen in the previously studied DMAP and 9-EtGua analogs (Table 3.1).9 The 
reduction potentials were determined relative to [AuCl(dien)]2+. The reduction potential of A is 
intermediate between the previously studied DMAP and 9-EtGua analogs, and the Au(III) 
oxidation state is stabilized relative to the AuClN3 coordination sphere. The reduction potential of 
B is slightly higher than the previously studied DMAP analog, but is still slightly lower than the 
chloride analog. 
Complex ΔEp (V) Ref. 
[Au(dien)(9-EtGua)]3+ -0.069 9 
[Au(dien)(DMAP)]3+ -0.048 9 
[Au(dien)(1-MeCyt)]3+ (A) -0.052  
[AuCl(N-Medien)]2+ +0.048 9 
[Au(N-Medien)(9-EtGua)]3+ +0.017 9 
[Au(N-Medien)(DMAP)]3+ +0.042 9 
[Au(N-Medien)(1-MeCyt)]3+ (B) +0.045  
 
3.4 Discussion 
The synthesis of complexes A and B serves to complete the series of complexes of the form 
[M(dien)(1-MeCyt)]n+, in which the Pt(II) and Pd(II) complexes, which are both isoelectronic and 
Table 3.1. Peak Potential Values (vs Ag/AgCl) for the reduction of selected Au(III) 
complexes at a Platinum disc electrode relative to [AuCl(dien)]2+. 
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isostructural to the Au(III) complexes investigated in this work, had been previously investigated, 
but the Au(III) analog had remained unreported up to this point. 
Tryptophan is present on the C-terminal zinc finger of NCp7, and plays an essential role in 
protein-DNA/RNA recognition, which occurs through a π-π stacking interaction between the 
aromatic tryptophan (or in the case of the full peptide, phenylalanine) residues and the nucleobases 
in DNA/RNA.13,19 Previously, it has been shown that association with free N-Acetyl-L-tryptophan 
(NAcTrp) is a good indicator of a compound’s affinity for the full protein. The fluorescent 
emission of NAcTrp can be quenched by a complex that interacts with NAcTrp in a π-π stacking 
interaction, and the degree to which the fluorescent emission is quenched is directly related to the 
strength of the interaction.9-11,13,15,17 
Compared to the Pt(II) and Pd(II) analogs, the Au(III) complexes show a higher affinity for 
NAcTrp, consistent with the previous literature.4,20 The lower affinity of B for NAcTrp than the 
DMAP and 9-EtGua analogs is surprising given the intermediate basicity of 1-MeCyt. The result 
for A is as expected, as the basicity of free 1-MeCyt is intermediate between that of DMAP and 9-
EtGua, but the results obtained for B and C show that there are factors other than the basicity that 
influence the associative interaction. Therefore, it is likely that the N-methyl group present on the 
chelating ligand in B causes a lower association constant for the π-π stacking interaction with 
NAcTrp than in A, shows that the modulation of the electronic environment of the metal center 
can influence the interactions between the complex and the protein recognition element. However, 
this reduction upon methylation of the chelating ligand is only observed to a lesser extent in the 9-
EtGua analog.  
Mass spectrometry studies with the previously reported Au(III) analogs showed that the 
formation of random coil observed by CD was accompanied by the formation of “gold fingers” in 
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which one or more atoms of gold replaced the zinc in the zinc finger structure upon zinc ejection.9 
The observation of oxidized apopeptide is indicative of disulfide bond formation between cysteine 
molecules of the same peptide, while the observation of oxidized dimerized apopeptide is 
indicative of disulfide bond formation between cysteine residues of different protein molecules. 
These interactions would likely be facilitated by the reduction of the metal center from Au(III) to 
Au(I)/Au(0). This interaction is in contrast to the interactions observed in the Pt(II) analogs, in 
which reduction and incorporation of the Pt(II) metal center is not seen, and instead the metal 
center is observed with the ligands intact and with the zinc still incorporated.4,17,20 As with the 
previously reported aurated DMAP and 9-EtGua analogs, but unlike the platinated analogs, peaks 
representing the unreacted zinc finger protein are not seen at the initial time point, highlighting the 
increased reactivity of the Au(III) metal center. The incorporation of four equivalents of gold was 
thought to be due to a difference in the redox properties of A and B when compared to the 
previously studied Au(III) analogs. Therefore, cyclic voltammetry studies were carried out in order 
to assess these differences. 
Cyclic voltammetry showed that it is significantly easier to reduce cytosine and thymine than 
it is to reduce adenine and guanine.21 In the context of interaction with zinc finger peptides, this 
reduction would be accompanied by disulfide bond formation. In this case, the greater ease of 
reduction may cause the occurrence of a charge transfer mechanism, in which the disulfide bond 
formation occurs across two equivalents of the peptide forming the oxidized dimerized peptide 
uniquely observed in the case of A and B, in contrast to the simple oxidation of one equivalent of 
zinc finger. Whereas this latter oxidation is easily understood with reduction of Au(III) to Au(I) 
and concomitant oxidation of two Zn-bound cysteines, the first step in peptide dimerization may 
be an electron transfer between the 1-MeCyt ligand to the tryptophan ligand. This suggestion 
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would explain why similar products would not be seen in the isostructural Pt(II) complexes, as the 
platinum center is not reduced upon interaction with zinc finger peptides, while a charge transfer 
mechanism must occur with concomitant reduction of the metal center.22 No evidence for self-
association was observed by NMR studies for A or for free ligands (Figure 3.10). Previously 
published work has discussed the reduction potential and accessibility of the cysteine residues of 
the C-terminal zinc finger, and this data suggests that disulfide bond formation would likely occur 
between C39 residues (Figure 3.11), as C39 has a reduction potential nearly as low as that of C49 
(-33.35 vs. -35.91 mV), but has a much greater accessibility (52.88 vs. 15.17).22 It is also possible 
that reduction of multiple molecules of A or B could also result in the formation of multiple 
disulfide bonds, in which case both C49 and C39 could form disulfide bonds to form the dimer.  
 
(a) 
(b) 
(c) (d) 
Figure 3.10. Self-association determination of (a) DMAP, (b) NAcTrp, (c) 9-
EtGua, and (d) A. In each case, self-association was negligible on the scale of 
association between the complexes and NAcTrp. 
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3.5. Materials and Methods  
[AuCl(dien)]Cl2 and [AuCl(N-Medien)]Cl2 were synthesized according to previously 
published procedures.23 1-Methylcytosine was synthesized and purified according to previously 
published procedures.24,25 Addition of the N-heterocycles were carried out analogously to 
previously published procedures.9 All NMR studies were carried out in deuterium oxide on a 
Bruker AVANCE III (400 MHz). CD studies were carried out at 50 µM concentrations in water 
on a Jasco J-1500 spectrometer. Mass spectrometry studies were carried out on a Thermo Electron 
Corporation Orbitrap Velos mass spectrometer. Mass spectrometry samples were prepared at 10 
µM concentrations in 10% methanol, and were sprayed at 2.30 kV and 0.9 µL/minute at 230 °C. 
Synthesis of [Au(dien)(1-Mecyt)](NO3)3 (A): [AuCl(dien)]Cl2 (101.2 mg, 0.249 mmol) was 
dissolved in dH2O (10 mL). 1-Methylcytosine (30.2 mg, 0.242 mmol) and Silver nitrate (125.4 
mg, 0.738 mmol) were added, and the reaction mixture was stirred under light protection for 72 
hours. The precipitated silver chloride was removed by filtration through celite, and the filtrate 
was evaporated to dryness under reduced pressure. The orange/yellow residue was dissolved in a 
small amount of dH2O, and acetone was added to the cloud point. The orange/yellow solid product 
was collected by vacuum filtration, and characterized by 1H-NMR, Infrared spectroscopy, and 
elemental analysis (experimental(theoretical)): C: 14.46% (14.62%) H: 2.81% (2.86%) N: 17.70% 
(17.17%). 1H NMR (D2O, 400 MHz): 7.83 (d, 0.35H), 7.73 (d, 0.65H), 6.14 (d, 1H), 3.69 (broad, 
Figure 3.11. Illustration of disulfide bond formation. Zinc coordinating residues are 
highlighted in red. 
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5.9), 3.45 (s, 3H), 3.18 (broad, 2.1H). UV-Vis (1 mM, H2O): 237 nm (Abs = 3.98), 357 nm (Abs 
= 0.408). 
Synthesis of [Au(N-Medien)(1-MeCyt)](NO3)3 (B): [AuCl(N-MeDien)]Cl2 (100.12 mg, 0.238 
mmol) was dissolved in dH2O (10 mL). Silver nitrate (121.4 mg, 0.715 mmol) and 1-
methylcytosine (29.8 mg, 0.238 mmol) were added and the reaction mixture was stirred under light 
protection for 4 days. The reaction mixture was filtered through celite and the solvent was 
evaporated under reduced pressure. The resulting crude product was dissolved in a small amount 
of water and excess acetone was added to precipitate the yellow product, characterized by 1H-
NMR, Far-IR, and elemental analysis (experimental(theoretical)): C: 16.77%(17.20%) H: 
3.33%(3.46%) N: 17.69%(18.05%). 1H NMR (D2O, 400 MHz): 7.82 (d,0.66H), 7.72 (d, 0.38H), 
6.13(d, 1H), 4.21 (d, 1.6H), 4.09 (m, 2.6H), 3.65 (m, 2.6H), 3.46 (d, 1.8H), 3.38 (s, 3H), 3.19 (m, 
2.4H). UV-VIS (1 mM, H2O): 237 nm (Abs = 3.94), 352 nm (Abs = 0.921). 
Synthesis of [Au(dien)(Cyt)](NO3)3 (C): [AuCl(dien)]Cl2 (100.44 mg, 0.168 mmol) was 
dissolved in dH2O (10 mL). Cytosine (28.2 mg, 0.164 mmol) and Silver nitrate (85.61 mg, 0.506 
mmol) were added, and the reaction mixture was stirred under light protection overnight. The 
precipitated silver chloride was removed by filtration through celite, and the filtrate was 
evaporated to dryness under reduced pressure. The orange residue was dissolved in a small amount 
of dH2O, and acetone was added to the cloud point. The orange solid product was collected by 
vacuum filtration. 1H NMR (D2O, 400 MHz): 7.64 (d, 1H), 6.06 (d, 1H), 3.52 (t, 4H), 2.99 (broad, 
4H). 
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Fluorescence Quenching of Tryptophan 
Tryptophan quenching methods were adapted from those previously published.9 A solution of 
N-acetyl-L-tryptophan (5 µM) was titrated with the Au(III) complexes (7.5 mM) in amounts 
ranging from 1-10 equivalents of quencher. 
Determination of Self-Association by NMR Spectroscopy 
Varying concentrations (0.1-2.5 mM) of N-heterocycle and gold(III) complex were analyzed 
by 1H-NMR. The degree of self-association was determined by previously published methods.26 
Microsoft Excel Solver was used to solve the three variable equation. 
Determination of Tryptophan Association by NMR Spectroscopy 
The association between NAcTrp and π-π stacking compounds was determined through the 
use of a Benesi-Hildebrand plot, adapted from the previously published method.19 
Cyclic Voltammetry 
Cyclic voltammetry studies were carried out following the previously published procedures.9 
A three-electrode cell was employed, containing a platinum disk working electrode, a platinum 
mesh counter electrode, and a silver/silver chloride reference electrode (0.1 M KCl). Solutions 
were degassed with nitrogen for 15 minutes before analysis. Measurements were obtained in 50 
mM phosphate buffer (4 mM NaCl, pH = 7.4). 
3.6 Conclusions 
In conclusion, the previously unreported 1-methylcytosine complexes based on the 
[Au(dien)(N-heterocycle)]3+ motif, A and B, have been synthesized and investigated for their 
ability to interact with the C-terminal finger of the HIV nucleocapsid protein NCp7 as a model for 
a protein with highly nucleophilic cysteines. Gold compounds are considered to primarily interfere 
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with protein, rather than DNA, function. In considering the series [M(dien)L]n+ the electronic 
properties can be modulated systematically for optimal protein interaction. A key feature leading 
to the rational design of complexes of the form [Au(dien)L]3+ is the enhancement of the redox 
stability of the complexes relative to the precursor [AuCl(dien)]2+ due to the incorporation of a 
more substitution inert nitrogen donor in the form of an N-heterocycle.9 In the case of the more 
sterically hindered complex B, the reduction potential is greater than the chloride analog [AuCl(N-
Medien)]2+, and is in line with the reduction in stabilization of the gold(III) oxidation state seen in 
the complex [Au(N-Medien)(DMAP)]3+.  Secondly, the aurated nucleobase may interact 
preferentially with an RNA(DNA) recognition motif such as tryptophan. Formation of oxidized 
dimerized peptide was observed in the mass spectrometry studies conducted with NCp7-F2 and 
indicated a difference in the reactivity profile of A and B compared to the previously studied 
DMAP and 9-EtGua analogs. These results further confirm that by tuning the electronic and steric 
properties of the ligands on the Au(III) coordination sphere, the strength of interaction between 
complexes of the [Au(dien)(N-heterocycle)]3+ motif and a zinc finger can be modulated in a 
systematic manner.  
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3.8 Appendix 
NMR Association Studies 
The inner filter effect is a concern in studies of the association of complexes of the [Au(dien)(N-
heterocycle)]3+ structure, as there is some overlap in the absorbance spectrum of the gold(III) 
complexes with the fluorescent absorption/emission spectra of N-acetyltryptophan. This overlap 
would artificially inflate the association value determined for a complex with N-acetyltryptophan, 
as the incident photons or emitted photons may be absorbed by the free gold(III) complex in 
solution. In order to address this issue, NMR experiments were carried out in order to investigate 
the potential of NMR as a method of determining the association between the gold(III) complexes 
and N-acetyltryptophan. In order to prove this concept, the free N-heterocycle DMAP was first 
investigated, as it is easily purchased at a low cost. However, DMAP has a fluorescence emission 
of its own, meaning the data previously obtained for association of DMAP with N-
acetyltryptophan by fluorescence quenching may also be artificially higher than expected. In order 
to confirm that the data obtained from the NMR determination of association constant was valid, 
the free N-heterocycle 9-Ethylguanine was also investigated, as the free 9-ethylguanine does not 
have any spectral overlap with the N-acetyltryptophan. Finally, A was investigated in order to 
determine the difference in show that this method can be applied to a gold(III) complex. In order 
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to confirm that the system was a simple equilibrium system, and not a system in which a pre-
association was present, the ability of the complexes to self-associate was also investigated by 1H-
NMR. The self-association of the complexes was determined using the equation 𝛿𝑜𝑏𝑠 = {[−𝐾𝑑 +
(𝐾𝑑
2 + 8𝐶𝐾𝑑)
1 2⁄ ]/4𝐶}(𝛿𝑀 − 𝛿𝐷) + 𝛿𝐷, where 𝛿𝑜𝑏𝑠 is the observed, or average, chemical shift, 𝛿𝑀 
is the chemical shift of the monomer, 𝛿𝐷 is the chemical shift of the dimer, and C is the total 
concentration of the molecule. On the scale of the associations with N-acetyltryptophan, any pre-
association was determined to be negligible. 
In addition, the binding stoichiometry of free DMAP and [Au(dien)(DMAP)]3+ with NAcTrp 
were investigated by Job’s method as previously described.27 The final total concentration was 2.5 
mM. 
 
0.1 Eq 
DMAP 
0.2 Eq 
0.3 Eq 
0.4 Eq 
0.5 Eq 
1.0 Eq 
1.5 Eq 
2.0 Eq 
Figure 3.12. 1H-NMR determination of the association between DMAP and N-
acetyltryptophan. 
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0.5 Eq 
1.0 Eq 
Figure 3.13. 1H-NMR determination of the association between 9-EtGua and N-
acetyltryptophan. 
0.1 Eq A 
0.25 Eq 
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5.0 Eq 
Figure 3.14. 1H-NMR determination of the association between A and N-acetyltryptophan. 
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Table 3.2. Association constants with N-acetyltryptophan as determined by Benesi-
Hildebrand treatment of 1H NMR data. 
 
Complex Ka (× 103 M-1) 
DMAP 0.236 
9-EtGua 1.54 
[Au(dien)(1-MeCyt)]3+ (A) 2.68 
 
 
2.5 mM 
1.0 mM 
0.5 mM 
0.25 mM 
0.1 mM 
A 
A 
B 
B 
C 
C 
Figure 3.15. 1H-NMR determination of the self-association of DMAP. 
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Figure 3.16. 1H-NMR determination of the self-association of N-acetyltryptophan. 
 
 
Figure 3.17. 1H-NMR determination of the self-association of 9-ethylguanine. 
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Table 3.3. Determination of the self-association of DMAP.  
B C D E F G H I J K L M N 
    
dObs C Kd Kd*-1 Kd^2 8CKd F+G (F+G)^.5 E+I/4c dm dD dm-dD J*M (N+L-B)=0 
   
7.2507 0.1 0.985318 
-
0.98532 0.970851 0.788254 1.759105 1.326313 0.852487 6.134568 9.210439 
-
3.07587 
-
2.62214 -0.6624 
  
Ka(avg) 1.013936 
7.2513 0.25 0.982208 
-
0.98221 0.964733 1.964417 2.92915 1.711476 0.729268 6.179607 9.096052 
-
2.91645 
-
2.12687 -0.28212 
    
7.2554 0.5 0.983541 
-
0.98354 0.967353 3.934163 4.901516 2.213937 0.615198 6.22124 8.991453 
-
2.77021 
-
1.70423 0.031823 
    
7.27 1 0.987283 
-
0.98728 0.974728 7.898265 8.872993 2.978757 0.497868 6.263999 8.885084 
-
2.62108 
-
1.30496 0.310129 
    
7.2833 2.5 0.992927 
-
0.99293 0.985904 19.85854 20.84444 4.565571 0.357264 6.315184 8.758931 
-
2.44375 
-
0.87306 0.602567 
    
 
Average 0.986255 
          
1.08E-09 
    
 
Stdev 0.004189 
               
 
B C D E F G H I J K L M N 
    
dObs C Kd Kd*-1 Kd^2 8CKd F+G (F+G)^.5 E+I/4c dm dD dm-dD J*M (N+L-B)=0 
   
6.821075 0.1 0.991789 -0.99179 0.983645 0.793431 1.777075 1.33307 0.853203 5.628532 8.830604 -3.20207 -2.73202 -0.72249 0.72249 
 
Ka(avg) 0.998283 
6.81615 0.25 0.9948 -0.9948 0.989627 1.9896 2.979228 1.726044 0.731244 5.696185 8.682557 -2.98637 -2.18377 -0.31736 
    
6.78025 0.5 1.000819 -1.00082 1.001638 4.003275 5.004913 2.237166 0.618174 5.75785 8.547614 -2.78976 -1.72456 0.042805 
    
6.76165 1 1.007608 -1.00761 1.015274 8.060865 9.076139 3.012663 0.501264 5.82077 8.409927 -2.58916 -1.29785 0.350426 
    
6.75235 2.5 1.013586 -1.01359 1.027357 20.27172 21.29908 4.615092 0.360151 5.89622 8.244816 -2.3486 -0.84585 0.646618 
    
 
Average 1.00172 
          
4.5E-10 
    
 
Stdev 0.008983 
               
Table 3.4. Determination of the self-association of N-acetyltryptophan. 
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Figure 3.18. 1H-NMR Job’s Plot of the interaction between free DMAP and NAcTrp. 
 
 
Figure 3.19. 1H-NMR Job’s Plot of the interaction between [Au(dien)(DMAP)]3+ and 
NAcTrp. 
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Chapter 4: Synthesis, Crystal Structure, and Protein 
Interactions of a Triphenylphosphine Au(C^N) 
Complex – Carbon-Sulfur Transfer Mechanisms on 
HIV NCp7 
James F. Beaton, Douglas H. Nakahata, Faik Musayev, Martin K. Safo, and Nicholas P. Farrell 
4.1 Abstract 
The synthesis, characterization, and crystal structure of the previously unreported complex 
[AuCl(dampa)(PPh3)]
1+ are detailed. The interactions of this complex, and of the previously 
reported AuCl2(dampa), with NCp7 and smaller models show the possibility for gold-mediated 
transfer of the dampa and triphenylphosphine ligands to the sulfur of the protein and models. These 
interactions provide a novel method of targeting zinc finger proteins. 
4.2 Introduction 
The HIV Nucleocapsid Protein (NCp7) is involved in many critical processes in the viral life 
cycle, and is an example of a zinc finger protein.1,2 NCp7 has two tetrahedrally coordinated zinc 
atoms, also known as zinc fingers, and modification or deletion of the zinc coordinating residues 
causes loss of protein function.3,4 This loss of function has a strong negative impact on the efficacy 
of the virus.4 Selective targeting of zinc finger proteins is a problem that has been widely discussed 
across the literature, but in many cases there are still significant challenges that must be addressed. 
The use of coordination complexes has been employed to obtain reactivity profiles that are 
unavailable through the use of organic molecules, including the leveraging of molecular 
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geometries and unique electronic properties to gain access to mechanisms of interaction beyond 
the use of an oxidation/reduction mechanism directly attacking the zinc coordinating residues. For 
example, the use of an N-heterocyclic ligand bound to a metal center such as Pt(II), Pd(II), or 
Au(III) allows for a π-π stacking with the tryptophan and phenylalanine residues.5–14 This stacking 
interaction allows for a much weaker electrophile to attack the neighboring cysteine residues due 
to the proximity between the electrophile and the zinc coordinating residues. In the case of these 
complexes, it was shown that the use of a metal center enhanced the π-π stacking ability of the N-
heterocyclic ligands to a greater extent than organic modification, highlighting the advantages of 
the use of coordination complexes in addressing complex challenges such as the selective targeting 
of zinc finger proteins. 
Reaction mechanisms other than π-π stacking followed by electrophilic attack can also be 
achieved through the use of coordination complexes. Additionally, the “soft” nature of gold also 
suggests that it should interact readily with sulfur containing biomolecules, and indeed this 
phenomenon is borne out in the literature.15,16 Most of the previous studies carried out between 
zinc finger proteins and gold-containing coordination complexes show that the major product is 
the replacement of the zinc ion with one or more gold atoms, referred to as the formation of “gold 
fingers”.10 Recently, however, Au(III) complexes containing a gold-carbon bond have been shown 
to have the ability to covalently modify polypeptides by transferring the C-donating ligand to a 
sulfur containing residue such as cysteine.17,18 This work was expanded to zinc finger proteins in 
the case of the complex Au(bnpy)Cl2 (bnpy = benzylpyridine), and it was shown that this covalent 
modification of the protein was possible by transfer of the benzylpyridine ligand to cysteine. This 
transfer is thought to occur by a ligand replacement, in which the cysteine replaces a gold bound 
chloride, followed by reductive elimination at the metal center, resulting in the covalent 
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modification of the zinc-coordinating residue.19 By leveraging the unique ability of Au(III) to 
undergo this reaction, and by making use of the observation that altering the Au(III) coordination 
sphere gives the ability to tune the reactivity of the complex, may lead to the development of a 
Au(III) complex with a favorable reactivity profile that is selective for NCp7. 
4.3 Results and Discussion 
The structures of the complexes studied are shown in figure 4.1. The crystal structure of A has 
been previously reported.20 Compound B crystallized in a monoclinic crystal system, Cc space 
group. The crystal structure is shown in figure 4.2. The asymetric unit confirms the formation of 
the Au-C^N chelate and the coordination of triphenylphosphine trans to the Au-N bond. The 
charge balance is achieved by the presence of hexafluorophosphate as a counterion, and 
chloroform molecule of crystallization was present. This configuration is contradictory to the 
expected geometry were the complex to follow the traditional trans-effect order of ligands. 
However, it is not the first time that a complex has defied the trans-effect when forming, and the 
phenomenon has previously referred to as “transphobia”, in which a destabilizing effect is 
observed when two soft ligands are trans to one another. Other complexes with the dampa ligand 
also exemplify this effect, so that substituents containing donor atoms of high trans influence, such 
as S and C, are always located trans to the N rather than the C.21–25 The gold atom deviates from 
planarity (as determined based on the four coordinating atoms) by 0.079 Å (r.m.s.), with a τ4 
parameter of 0.13.26 The –CH2– group of the dampa ligand is located 0.466 Å away from the plane 
defined by N1–Au1–C1–C6, which may explain the observed splitting of the protons in the NMR 
spectrum.  
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The main bond lengths and angles for B are listed in Table 4.1.  The Au-N bond length was 
2.141 Å, which consistent with the average for previously reported complexes of with similar C^N 
chelating systems of 2.12(7) Å. The Au-C bond length of 2.049 Å is shorter than the Au-N 
distance, and is also consistent with the average for previously reported complexes of 2.03(4) Å. 
This is consistent with the strong σ-donor character of the deprotonated phenyl ring. The Au-P 
bond length is the longest of the gold-coordinated ligands at 2.300 Å, but this is also consistent 
with the average Au-P bond length for reported Au(III) complexes of 2.30(2) Å. The crystal 
packing is stabilized by non-classical hydrogen bonding between the dampa CH2 and the fluorine 
of hexafluorophosphate. This interaction is also present between the benzene hydrogen atoms and 
both the fluorine of hexafluorophosphate and chlorine of chloroform. The supramolecular structure 
of B is mainly formed by non-classical hydrogen bonding between the gold complex, 
hexafluorophosphate, and chloroform (see Appendix). 
A B 
Figure 4.1. The structure of complex A (top left), B (top right), and NCp7 (bottom). 
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Table 4.1. Selected bond lengths (Å) and bond angles (°) of the crystal structure of B. 
 
 
Figure 4.2. Molecular view of compound B. Displacement ellipsoids are drawn at the 50% 
probability level. The chloroform molecule was omitted for clarity. 
Au1–C1 2.049 (13) C1–Au1–N1 82.1 (5) 
Au1–N1 2.141 (10) P1–Au1–Cl1 91.15 (11) 
Au1–P1 2.300 (3) N1–Au1–Cl1 91.1 (3) 
Au1–Cl1 2.360 (4) C1–Au1–P1 95.5 (4) 
 
In order to investigate the potential for A and B to target cysteine, the reaction between N-
Acetyl-L-Cysteine (NAcCys) was studied by NMR spectroscopy (Figure 4.3) and mass 
spectrometry (Figure 4.6). Immediately upon mixing a 1:1 solution of A or B with NAcCys, the 
1H-NMR signals for the chelate aromatic protons and the NAcCys protons show that a reaction is 
underway. After 12 hours of time has elapsed, the signals have resolved, indicating that the reaction 
is complete and that a new product had formed. Additionally, in the NMR spectra of A and B the 
chelate –CH2- peak is resolved into a singlet. This is in contrast to the analogous AuCl2(bnpy), in 
which the rigid steric constraints imposed by the pyridine moiety cause splitting of the –CH2- 
Au1
Cl1
N1
P1
C1
P2
o
a
b c
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protons.19 This phenomenon was also previously observed in the complex [Au(BPMA)Cl]2+ 
(BPMA = di-2-(picolyl)amine), and shows that there is the potential for modulation of the steric 
properties of the chelate, which could be leveraged to investigate new structure-activity 
relationships in order to effectively target NCp7.27 However, this makes the NMR spectrum of the 
reaction product somewhat more difficult to interpret, as the resolution of the split peaks into a 
singlet was used to confirm C-S transfer in the case of Au(bnpy)Cl2.
19  
 
 
In order to determine the identity of the product that formed, a 1:1 mixture of A and NAcCys 
was examined by mass spectrometry. After 24 hours, signals representative of [dampa-Au-
NAcCys] (m/z = 493.0801, 1+) and the carbon-sulfur transfer product [dampa-NAcCys] (m/z = 
297.1237, 1+) are observed, confirming that the product observed by NMR is the result of a C-S 
transfer process. A 1:1 mixture of B and NAcCys showed presence of similar products, however 
in some cases two equivalents of dampa were observed bound to cysteine (m/z = 423.2828, 1+). 
Figure 4.3. Interaction of A with NAcCys at time of mixing and 12 hours. 
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Similar studies were carried out using glutathione (GSH) to investigate the ability of A and B 
to interact with a larger sulfur containing biomolecule. As in the case of NAcCys, NMR 
spectroscopy shows that a distinct product has formed after 12 hours of reaction time (Figure 4.4). 
Similarly to the reaction with NAcCys, the mass spectrum of a 1:1 mixture of A and GSH showed 
formation of both the gold-bridged intermediate dampa-Au-GSH (m/z = 637.1356, 1+) and the C-
S transfer product dampa-GSH (m/z = 441.1782, 1+) (Figure 3). Additionally, a signal representing 
[Au(dampa)]2-GSH was observed (m/z = 966.1831, 1+). After 24 hours, the signals for all three 
products were still present, indicating that the reaction was incomplete or that it is possible for the 
final product to contain a bridging gold atom. Unlike the previously investigated Au(bnpy)Cl2, the 
C-S transfer product was observed and the signal for oxidized glutathione (GSSG+, m/z = 613.15) 
was not observed, indicating that reduction of the metal center is coupled to the C-S transfer 
Figure 4.4. Interaction of B with NAcCys at time of mixing (bottom), 6 hours (middle), and 
24 hours (top). 
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process in the case of A.19 Mass spectrometric analysis of a reaction of B and GSH showed that 
identical products formed despite the presence of the triphenylphosphine ligand (Figure 4.7). 
 
 
 
Figure 4.5. Interaction of B with NAcCys at time of mixing and 24 hours. 
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Figure 4.6. Interactions of A with NAcCys (left) and GSH (right). 
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The triphenylphosphine ligand on B also allows for the use of 31P-NMR as a tool for elucidating 
the nature of the product formed. The chemical shift of the triphenylphosphine ligand on B appears 
at 36.94 ppm (relative to trimethylphosphate). This is a significant downfield shift with respect to 
previously reported Au(I) complexes, which appear at roughly 30 ppm.28 The interactions of B 
with NAcCys and GSH are shown in figures 4.8 and 4.9 respectively. The 31P-NMR studies 
conducted confirm that a reaction occurs between B and the sulfur containing molecules. After 24 
hours of incubation time with NAcCys, an upfield shift is observed. The final product has a 
chemical shift of 32.13 ppm. The upfield shift observed in this case is in contrast to the product 
observed when Au(I) complexes are incubated with NAcCys, which produces a downfield shift 
and a final chemical shift of roughly 39 ppm. Instead, the final product has a chemical shift closer 
to the chemical shift of the previously studied Au(I) complexes, supporting the proposed reductive 
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Figure 4.7. Mass spectrum of the product of the interaction of B with GSH after 24 hours. 
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elimination mechanism of C-S transfer, which would produce a triphenylphosphine containing 
Au(I) complex as a product.28 
 
After 24 hours of incubation with GSH, two product peaks are observed, both of which are 
shifted upfield from B. The larger of the two has a chemical shift of 31.27 ppm and is likely the 
Au(I) reductive elimination product as seen in the reaction with NAcCys. The second smaller peak 
has a chemical shift of 23.17 ppm and may be representative of the intermediate in which the C-S 
transfer is not complete, indicating that the reaction is slower in the case of the more sterically 
hindered GSH. However, it is also possible that this peak is the result of the previously reported 
“ligand scrambling” effect observed in the case of phosphine-containing Au(I) complexes, but this 
is unlikely, as ligand scrambling has been reported to cause a downfield shift rather than an upfield 
shift.28 
Figure 4.8. Interaction of B (bottom) with NAcCys after 24 hours (top) monitored by 31P-
NMR. 
 
129 
 
 
Upon interaction with the full NCp7 protein, a variety of products were identified by mass 
spectrometry (Figure 4.10). Immediately after mixing a solution of NCp7 with one equivalent of 
A per zinc finger, the presence of signals corresponding to both the gold bridged product, Peptide-
(Au(dampa))2 (m/z = 850.9478 (7+), 744.8303 (8+), 662.0722 (9+)), and the C-S transfer product, 
Peptide-(dampa)2 (m/z = 617.2978 (9+), 556.5256 (10+)), were observed (where peptide is NCp7 
in which the two coordinated zincs have been lost). The C-S transfer signals were present at a 
significantly lower abundance at this timepoint. Other signals that were identified include the 
formation of gold fingers with 2 (m/z = 677.1949 (8+), 609.6763 (9+)) and 5 (m/z = 909.3537 (8+), 
808.5375 (9+)) equivalents of gold per finger were observed. Signals corresponding to [Peptide-
Au7-dampa2] (m/z = 992.1113 (7+), 868.2231 (8+), 771.8650 (9+), 694.8798 (10+)) may be 
representative of an intermediate in which a gold finger containing 5 gold atoms is formed in place 
of one zinc finger, and gold bridged cysteines are present on the other finger. Signals 
Figure 4.9. Interaction of B (bottom) with GSH after 24 hours (top) monitored by 31P-NMR. 
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corresponding to [Peptide+Au+dampa] (m/z = 937.9295 (6+), 804.0841 (7+), 703.6997 (8+), 
625.6223 (9+), 563.1609 (10+)) were also present in high abundance at the initial timepoint, which 
likely represent a peptide sequence in which one of the fingers has become a gold finger, and the 
other has complexed dampa through a C-S transfer reaction. This binding motif is more probable 
than a gold-bridged motif in this case, as both zinc atoms are lost. Interestingly, at the initial 
timepoint, signals representing [Peptide-(Au(dampa)Cl)2] were observed (669.1698 (9+), 
1002.5328 (6+)). This further shows that incorporation of the Au-C bond significantly slows the 
reaction between the gold complex and the protein, as in most previous examples chloride is not 
observed bound to gold at even the earliest timepoints. 
 
  
Figure 4.10. Interaction of A with NCp7 immediately after mixing. 
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Table 4.2. Products of the reaction between A and NCp7 identified by mass 
spectrometry immediately after mixing. 
Product Identity Theoretical m/z Observed m/z 
Peptide + Au + dampa 703.718+ 703.708+ 
 625.639+ 625.629+ 
 563.1710+ 563.1610+ 
Peptide + 2(Au) + 2(dampa) 850.957+ 850.957+ 
 744.718+ 744.838+ 
 662.089+ 662.079+ 
Peptide + 7(Au) + 2(dampa) 992.087+ 992.117+ 
 771.849+ 771.879+ 
 694.7610+ 694.8810+ 
Peptide + 10(Au) 909.428+ 909.358+ 
 808.499+ 808.549+ 
 
 
After 24 hours of incubation with A (Figure 4.11), the most readily observable signals were 
those of [peptide-Au4-(dampa)2] (m/z = 1057.9220 (6+), 907.0779 (7+), 793.8193 (8+), 705.7289 
(9+)). In this case, it is possible that the two equivalents of dampa are bridged by gold in the form 
[peptide-{Au(dampa)}2-Au2] in which dampa is still gold bridged, but it is also possible that all of 
the gold atoms and dampa ligands are bound to the peptide separately. The second most prominent 
set of signals present after 24 hours is that of the form [Peptide-Au2-(dampa)2-Cl2] (m/z = 
1002.0646 (6+), 858.9129 (7+), 751.9252 (8+), 669.1960 (9+), 602.3768 (10+)). The presence of 
these signals after 24 hours indicates that the gold bound to chloride state is significantly longer 
lived than in the previously studied AuN4 complexes, in which gold bound to chloride was not 
observed after any significant length of time. In fact, even in the analogous complex Au(bnpy)Cl2 
(another complex with an Au-C bond), gold bound chloride was not observed19. Other signals 
observed after 24 hours of incubation include [Peptide-(dampa)2] (m/z = 617.5116 (9+), 555.9616 
(10+)), which is also observed at the initial timepoint, and signals representing the peptide with 
two gold fingers with two gold atoms each, [Peptide-Au4] (m/z = 760.5781 (8+), 676.1805 (9+), 
608.6635 (10+)), and peptide with two gold fingers with five gold atoms each, [Peptide-Au10] (m/z 
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Table 4.3. Products of the reaction between A and NCp7 identified by mass 
spectrometry 24 hours after mixing. 
 
= 1039.1155 (7+), 909.4774 (8+), 808.5365 (9+)). The formation of gold fingers is analogous to 
the reactivity profile seen in the previously investigated gold(III) complexes possessing an AuN4 
coordination sphere, and shows that although a different product, in the form of the C-S transfer 
product, is obtainable through the use of the Au-C containing complex, mechanisms similar to the 
previously observed are still possible10. In the case of A, it is likely that the two labile Au-Cl bonds 
are responsible for the formation of gold finger products, as even at the initial timepoint the 
formation of the gold finger motifs were observed (ex. [Peptide-Au7-(dampa)2]). 
 
 
Product Identity Theoretical m/z Observed m/z 
Peptide + 4(Au) + 2(dampa) 1057.936+ 1057.926+ 
 906.947+ 907.087+ 
 793.708+ 793.828+ 
 705.629+ 705.739+ 
Peptide + 2(Au) + 2(dampa) + 2(Cl) 1002.086+ 1002.066+ 
 859.077+ 858.917+ 
 669.179+ 669.209+ 
 602.3610+ 602.3810+ 
Peptide + 2(dampa) 617.529+ 617.519+ 
 555.9710+ 555.9610+ 
Peptide + 10(Au) 808.499+ 808.549+ 
Peptide + 4(Au) 608.6510+ 
677.179+ 
760.308+ 
608.6610+ 
677.199+ 
760.298+ 
Figure 4.11. Interactions of A (left) and B (right) with NCp7 after 24 hours. Product 
configurations shown in the figure legends but not seen in the spectrum are shown in the 
tables. 
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Table 4.4. Products of the reaction between B and NCp7 identified by mass 
spectrometry 24 hours after mixing. 
 
Identity Theoretical m/z Observed m/z 
Peptide + 2(PPh3) + 4(Au) 944.09
7+ 944.097+ 
 826.218+ 826.208+ 
Peptide + 2(PPh3) + 3(Au) 916.10
7+ 916.097+ 
 801.718+ 801.718+ 
 712.749+ 712.749+ 
Peptide + 3(dampa) + 3(PPh3) + 3(Au) 885.01
8+ 884.988+ 
Peptide + 2(dampa) + 2(PPh3) + 4(Au) + 4(H) 860.49
8+ 860.498+ 
Peptide + 4(dampa) + 2(PPh3) + 2(Au) 844.51
8+ 844.458+ 
Peptide + 4(dampa) + 2(PPh3) + 1(Au) 937.02
7+ 937.097+ 
 820.028+ 819.958+ 
Peptide + 4(dampa) + 2(PPh3) + 2(H) 795.52
8+ 795.468+ 
Peptide + 2(PPh3) + 2(Au) + 2(H) 777.22
8+ 777.218+ 
 690.979+ 690.979+ 
Peptide + 3(dampa) + 3(PPh3) + 2(Au) + H 765.01
9+ 764.999+ 
 
 
In order to observe the effects of the bulky PPh3 ligand of the reactivity profile of complexes of 
this form, one equivalent of B per zinc finger was incubated with NCp7. Immediately after mixing, 
few identifiable products were observed (Figure 4.12). Peaks representing [Peptide-Au3-(PPh3)2] 
(m/z = 916.0926 (7+)), [Peptide-Au3-(dampa)3-(PPh3)3] (884.6648 (8+)), and [Peptide-Au2-
(dampa)-(PPh3)-H] (761.2114 (8+)) were observed. Especially at this early timepoint, the product 
configuration is difficult to predict, as the ligands may remain bound to the gold, or may have been 
transferred onto the peptide. 
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Table 4.5. Products of the reaction between B and NCp7 identified by mass 
spectrometry immediately after mixing. 
 
 
Product Identity Theoretical 
m/z 
Observed 
m/z 
Peptide + 2(PPh3) + 3(Au) 916.97
7+ 916.967+ 
Peptide + 3(dampa) + 3(PPh3) + 3(Au) 884.63
8+ 884.668+ 
Peptide + (dampa) + (PPh3) + 2(Au) 761.21
8+ 761.218+ 
 
 
After 24 hours of incubation, a multitude of products were identified. The most intense signal 
after 24 hours corresponds to the peptide with two equivalents of triphenylphosphine and three 
equivalents of gold bound, [Peptide-(PPh3)2-Au3] (m/z = 916.0926 (7+), 801.7065 (8+), 712.7398 
(9+)). The structure [Peptide-(PPh3)2-Au4] (m/z = 944.0854 (7+), 826.2005 (8+)) was also 
identified. These structures do not contain the ligand dampa, and show that the triphenylphosphine 
ligand may contribute to preventing the C-S transfer mechanism. In these products, it is possible 
that the triphenylphosphine ligand has dissociated from the gold and bound to the protein in an P-
Figure 4.12. Interaction of B with NCp7 immediately after mixing. 
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S transfer mechanism analogous to the C-S mechanism previously observed, but it is also possible 
that the products are bound in a [Peptide-Au-PPh3] motif, in which the metal center is reduced to 
gold(I) upon loss of the additional ligands. Some products were identified which retained the 
ligand dampa. These products include [Peptide-(dampa)3-(PPh3)3-Au3] (m/z = 884.9809 (8+)), 
[Peptide-(dampa)2-(PPh3)2-Au4] (m/z = 860.4858 (8+)), [Peptide-(dampa)4-(PPh3)2-Au2] (m/z = 
844.4468 (8+)), [Peptide-(dampa)4-(PPh3)2-Au1] (m/z = 936.9445 (7+), 819.9527 (8+)), [Peptide-
(dampa)4-(PPh3)2] (m/z = 795.4580 (8+), 690.9666 (9+)), [Peptide-(PPh3)2-Au2] (m/z = 777.2117 
(8+)), and [Peptide-(dampa)3-(PPh3)3-Au2] (m/z = 764.9870 (9+)). Of particular interest are the 
signals representing [Peptide-(dampa)4-(PPh3)2] and [Peptide-(dampa)4-(PPh3)2-Au], which serve 
to indicate that the P-S transfer mechanism, analogous to the previously reported C-S transfer 
mechanism, is possible, as both of these products contain a greater number of equivalents of 
triphenylphosphine than gold. However, in the studies with the small molecule models NAcCys 
and GSH this transfer mechanism was not observed, which may indicate that P-S transfer is only 
favorable if there is a large amount of steric bulk present around the site of reaction. Again, the 
exact configuration of the products is difficult to predict and warrants further experimentation. 
4.4 Conclusions 
In conclusion, gold mediated transfer of C-donor and P-donor ligands to sulfur containing 
biomolecules were observed in the study of complexes A and B with NCp7. Additionally, the 
crystal structure of the previously unreported complex B is detailed, and shows that the 
triphenylphosphine ligand is trans to the nitrogen of dampa, illustrating “transphobia” in the 
formation of complexes of this nature. The gold mediated C-S and P-S transfer mechanisms 
discussed herein offer new and interesting pathways for the targeting of zinc finger protein, 
allowing for the covalent modification of residues vital to the biological function of the protein, 
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and show that complexes of this form may provide a platform for the development of agents 
capable of selectively targeting NCp7. As such, additional investigation into the structure activity 
relationships of complexes of this form is warranted in order to tune the reactivity with, and 
therefore selectivity for, zinc finger proteins such as HIV-NCp7. 
4.5 Experimental Section 
Materials 
All reagents were purchased from Sigma Aldrich, and were used without further purification. 
Complex A was synthesized according to previously published methods.20 The NCp7 zinc finger 
(SNAIVKCFNCGKEGHIARNCRAPRKKGCWKCGKEGHQMKDCTERQAN, zinc 
coordinating residues highlighted in red) was a generous gift from Dr. Yangzhong Liu. Solutions 
of NCp7 were prepared by dissolving NCp7 in water at concentrations of 1 mg/mL (184 µM), and 
this stock was diluted as necessary. 
Synthesis 
Synthesis of [AuCl(dampa)(PPh3)](PF6) (B): Complex B was synthesized by an adaptation of 
previously published methods. Complex A was dissolved in acetone. Triphenylphosphine () and 
potassium hexafluorophosphate were added, and the reaction mixture was stirred for 16 hours. The 
solvent was evaporated under reduced pressure, and the residue was taken up in dichloromethane. 
The suspension was filtered, and the filtrate was evaporated to a small volume under reduced 
pressure. Diethyl ether was added, causing precipitation of the white product (62.3 mg, 62.7% 
yield). Elemental analysis (experimental(theoretical)) for C27H27NAuClF6P2: C: 41.61%(41.91%), 
H: 4.27%(3.52%), N: 1.78%(1.81%). Diffraction quality crystals of B were grown by slow 
evaporation of a solution of B in chloroform. 
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X-Ray Determination of Crystal Structure 
Data collection for the single-crystal of B was performed at 100 K using a Rigaku MicroMax-
007 HF X-ray generator, an EIGER R 4M detector and an Oxford Cobra cryosystem with Cu - Kα 
(λ = 1.54184 Å) radiation. Data collection, cell refinement and data reduction were performed 
using CrysALIS PRO 1.171.40.4a (Rigaku OD, 2018). The structure was solved with the SHELXT  
structure solution program using intrinsic phasing and refined as an inversion twin with SHELXL 
in Olex2.29–31 All nonhydrogen atoms were refined anisotropically and hydrogen atoms were added 
to the structure in idealized positions and refined according to the riding model. Molecular graphics 
were generated using Mercury (v. 1.10).32 Searches on the Cambridge Structural Database (CSD, 
v. 5.39) were performed in Conquest (v. 1.22)33 and Mercury. Crystallographic information of B 
can be found in Table 4.6.  
NMR Spectroscopy Studies 
1H and 31P NMR studies were recorded on a Bruker AVANCE III 400 MHz spectrometer. 1H 
NMR samples were referenced to the resonances of the solvent, and 31P NMR samples were 
referenced to an internal standard of trimethylphosphate. 
Mass Spectrometry Studies 
Mass spectrometry studies were carried out on a Thermo LTQ-Velos mass spectrometer. 
Complexes A and B were incubated with NAcCys and GSH in 1:1 molar ratios, and were incubated 
with NCp7 at molar ratios of 1 equivalent of complex per zinc finger. Studies involving NCp7 
were carried out at 10 µM concentrations in a solution of 10% methanol. Studies involving 
NAcCys and GSH were carried out at 1 µM concentrations in a solution of 10% methanol. I both 
cases, the spray voltage was 2.3 kV. 
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Table 4.6. Experimental details for crystal structure determination and 
refinement of B. 
 
Chemical formula C27H27AuClNP·F6P·CHCl3 
Molecular weight (g·mol-1) 893.22 
Crystal system, space group Monoclinic, Cc 
Temperature (K) 100 
a, b, c (Å) 25.1639 (3), 8.6579 (1), 17.0485 (2) 
β (°) 120.552 (2) 
V (Å3) 3198.63 (9) 
Z 4 
μ (mm-1) 13.17 
Crystal size (mm) 0.26 × 0.18 × 0.05 
Tmin, Tmax 0.105, 0.809 
No. of measured, independent and observed [I 
> 2σ(I)] reflections 
53335, 5479, 5462 
Rint 0.052 
R[F2 > 2s(F2)], wR(F2), S 0.039, 0.103, 1.04 
No. of reflections 5479 
No. of parameters 382 
No. of restraints 2 
Δmax, Δmin (e·Å-3) 2.96, −1.29 
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4.7 Appendix 
Supramolecular features of the [AuCl(dampa)(PPh3)](PF6) crystal structure 
The crystal packing of [AuCl(dampa)(PPh3)](PF6) (Figure 4.13(a)) is mainly formed by non-
classical hydrogen bonding. Every fluorine atom of the PF6
- counter ion is involved in hydrogen 
bonds, some of which are described in Table 4.7 and shown in Figure 4.13(b). Interestingly, two 
bifurcated hydrogen bonds motifs can be observed in this structure, one in which the chloroform 
molecule acts as a double donor (C28—H28···F6iv and C28—H28···F1iv in Table 4.7) and the 
other where F6 is a double acceptor (C7—H7A···F6iii and C8—H8B···F6iii in Table 4.7). The 
chlorine atoms from the chloroform molecule are also acceptors of H-bonding from either H of 
the triphenylphosphine ligand or the aryl ring from the dampa ligand (see C5—H5···Cl3ii in Table 
4.7 as an example). 
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Figure 4.13. (a) Packing of the crystal structure of [AuCl(dampa)(PPh3)](PF6), with view 
along b axis and (b) the non-classical hydrogen bonds involving the PF6
- counter-ion. 
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D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) 
C4—H4···F3i 0.95 2.53 3.470(14) 170.3 
C5—H5···Cl3ii 0.95 2.86 3.493 (14) 125.2 
C7—H7A···F6iii 0.99 2.55 3.457(15) 152.2 
C7—H7B···F5 0.99 2.45 3.198(16) 132.2 
C8—H8B···F6iii 0.98 2.44 3.393(17) 163.2 
C28—H28···F6iv 1.00 2.31 3.266(15) 160.1 
C28—H28···F1iv 1.00 2.57 3.387(15) 139.1 
[Symmetry codes: (i) x, −y+1, z+1/2; (ii) x−1/2, y−1/2, z; (iii) x, y−1, z; (iv) x+1/2, y−1/2, z.] 
 
Although π···π stacking interactions are absent in this crystal structure, a C—H···π 
interaction helps the lattice formation along the b axis, as shown in Figure 4.14. The interaction 
occurs between the C13—H13 donor of one of the phenyl rings of the triphenylhoshine and the 
phenyl ring of the dampa ligand (C13—H13···Cg1v 2.85Å). 
 
 
  
H13C13
Cg1v
b
a
Table 4.7. Hydrogen bonding geometry of the [AuCl(dampa)(PPh3)](PF6) crystal. 
Figure 4.14. The intermolecular C–H···π interaction present in [AuCl(dampa)(PPh3)](PF6). 
Displacement ellipsoids are drawn at the 50% probability level. [Symmetry code: (v) x, -1+y, 
z.] 
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Characterization Data 
 
 
Figure 4.15. Far-IR characterization of A (bottom) and B (top). 
Figure 4.16. 13C-NMR spectrum of A. 
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Figure 4.17. 1H/13C-HSQC spectrum of A. 
Compound B 
Free PPh
3
 
Figure 4.18. 1H-NMR spectrum of B (top) and free triphenylphosphine (bottom). 
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Figure 4.19. Mass spectrum of B. 
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Chapter 5: Differences in the Reaction Products of 
Gold(I) and Gold(I) Complexes with a Short Peptide 
Sequence 
5.1 Introduction 
The short model for the relevant binding sequence of the C-terminal zinc finger from the Sp1 
transcription factor, ACPECP, was found to form the unique bridged species {ACPECP-2[Pt(en)]} 
(en = ethylenediamine) upon a 1:1 interaction between [PtCl2(en)] and ACPECP
1. Additionally, 
ion mobility mass spectrometry studies were used to elucidate the site of interaction between the 
gold(I) complex [(PEt3)AuCl] and the C-terminal zinc fingers of NCp7 and Sp1
2. In the case of 
NCp7, the “gold finger” products formed were gold(I) crosslinks, and the coordinating residues 
gave the products the forms [Cys36-Au(I)-Cys49] and [Cys39-Au(I)-Cys49]. The experimental data 
for the interaction with Sp1 confirmed Cys5 as one of the gold-coordination sites, and either His20 
or His24 as the second binding site, giving the final product the conformation [Cys5-Au(I)-
His20/24]2. This data shows that platinum(II) and gold(III) can coordinate similar peptide sequences 
with different modes of binding. In order to expand this work to systems with gold(III) metal 
centers, the interaction of the short peptide sequence ACPECP was interacted with gold(III) 
complexes containing the tridentate chelating ligand diethylenetriamine, and these interactions 
were compared to the interaction of ACPECP with the gold(I) complex [(PCy3)AuCl] (PCy3 = 
tricyclohexylphosphine). 
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5.2 Experimental 
Synthesis of Chlorotricyclohexylphosphinegold(I) ([(PCy3)AuCl]): 
Chlorotricyclohexylphosphinegold(I) was synthesized by methods adapted from the previously 
published method3. Sodium tetrachloroaurate hyrdate (41.5 mg, 0.115 mmol) was dissolved in 500 
µL ethanol. Tricyclohexylphosphine (70.0 mg, 0.250 mmol) was dissolved in 500 µL chloroform, 
and the solutions were combined, resulting in the immediate precipitation of a white needle-like 
solid.  The reaction mixture was stirred for one hour.  The white solid product was collected by 
vacuum filtration and washed with acetone and diethyl ether.  The product was dried under vacuum 
and characterized by 1H-NMR and 31P-NMR. 1H-NMR (CDCl3, 400 MHz): δ 1.75, m. 31P-NMR: 
δ 53.9, s. Yield: 25.4 mg, 41.5%.  
5.3 Results 
The mass spectrum of a 1:1 mixture of [AuCl(dien)]2+ and ACPECP showed signals 
representing both oxidized peptide, indicative of the formation of a disulfide bond across the 
cysteine residues, and the gold bridged species, in which a single atom of gold is bound between 
the cysteine residues. The products of the reaction with [Au(N-Medien)(1-MeCyt)]3+ are the same 
as the products of the reaction with [AuCl(dien)]2+. In both cases, product formation occurs much 
more rapidly than was observed when ACPECP was interacted with platinum(II) species. In both 
cases, the signal for the oxidized peptide is significantly stronger than the signal observed for the 
gold-coordinated species. This may be due to the small number of peptides between the cysteine 
residues, which could result in a distance too short to easily form the linear coordination geometry 
that is preferred by gold(I). The signal representing the gold bound species is seen at m/z = 813.15, 
indicating that the gold(III) metal center is reduced to gold(I) upon coordination, which results in 
the loss of two protons from the total mass. 
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The mass spectrum of a 1:1 mixture of [(PCy3)AuCl] and ACPECP also resulted in the 
formation of both oxidized peptide and the gold-bridged species. Additionally, signals representing 
the products of ligand scrambling, as observed in previous studies with gold(I)-trialkylphosphine 
complexes, were observed4. The signal representing the gold bridged species is seen at m/z = 
815.17, indicating that coordination to the cysteine residues occurs without reduction of the gold(I) 
metal center. 
5.4 Discussion 
Interaction of one equivalent of three gold complexes, [AuCl(dien)]2+, [Au(N-Medien)(1-
MeCyt)]3+, and [(PCy3)AuCl] with one equivalent of the short peptide ACPECP was investigated 
by mass spectrometry. The binding properties of gold complexes with ACPECP is worthy of 
investigation, as ACPECP is the polynucleotide binding sequence of the C-terminal zinc finger of 
Sp1. The investigation of gold complexes as zinc finger proteins has been undertaken, but the 
differences in the reaction mechanisms between gold(I) and gold(III) complexes have not been 
thoroughly studied. The oxidation of the peptide sequence, observed at m/z = 617.20 (1+), is 
indicative of disulfide bond formation. Oxidized peptide is observed unilaterally upon interaction 
of gold complexes with zinc finger proteins4–6. In the case of this short model sequence, the 
oxidation takes the form of disulfide bond formation across the two cysteine residues. In order to 
maintain oxidation/reduction balance, the oxidation of the cysteine residues is likely coupled to 
the reduction of the metal center. 
The gold bridged oxidized peptide is where differences in the products between the reaction 
with gold(I) and gold(III) complexes can be observed. Both of the gold(III) complexes that were 
investigated formed a gold bound product observed as a signal at m/z = 813.15 (1+). Conversely, 
the product of the interaction with the gold(I) complex formed a gold bridged species observed as 
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a signal at m/z = 815.17 (1+). The difference in mass to charge ratio of 2.02 is indicative of two 
additional protons present on the product of the reaction with gold(I). This difference is caused by 
the ligand substitution reactions on the gold(I) metal center without reduction. Conversely, the 
lower observed mass to charge ratio after interaction of the gold(III) complexes is the result of the 
loss of two protons, which indicates that the metal center was reduced from gold(III) to gold(I) 
upon binding. The oxidation of the peptide is likely the result of disulfide bond formation. In order 
for disulfide bond formation to occur, the reduced metal center must bond to a different location 
on the peptide chain, such as an amine or carboxylate moiety. This result is further evidence that 
tuning the electronic properties of the metal center can allow for fine-tuning of the reactivity with 
proteins. 
 
Figure 5.1. Mass spectrum obtained from a 1:1 mixture of [AuCl(dien)]2+ and ACPECP. 
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Figure 5.3. Mass spectrum obtained from a 1:1 mixture of [(PCy3)AuCl] and ACPECP. 
 
Figure 5.2. Mass spectrum obtained from a 1:1 mixture of [Au(N-Medien)(1-
MeCyt)]3+ and ACPECP. 
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Chapter 6: General Conclusions 
 
Up to 10% of the human genome codes for zinc finger proteins. The diverse set of functions 
of zinc finger proteins makes them an excellent candidate for study, and a number of different zinc 
fingers have been identified as potential targets for chemical intervention. In the case of NCp7, the 
development of a selective inhibitor has the potential to make significant progress in the treatment 
of HIV. This is due to the high conservation of NCp7, as well as the high number of viral life cycle 
processes in which it is involved. A selective inhibitor of NCp7 would prevent the interaction 
between NCp7 and its natural polynucleotide substrate. The most promising strategy for 
preventing this interaction is the modification of the zinc coordination sphere, resulting in the 
ejection of zinc. Zinc ejection has been shown to inhibit the recognition of NCp7’s natural substrate 
and causes noninfectious virions.  
While many examples of complexes, both organic and inorganic, that eject zinc from NCp7 
have been described, a complex that achieves zinc ejection with a satisfactory degree of selectivity 
has not been developed. To this end, inorganic complexes with a “formally substitution-inert” 
coordination sphere have been investigated. These complexes contain an NCp7 recognition 
element in the form of a nucleobase or N-heterocycle. In theory, a substitution-inert complex that 
utilizes a structural element that imparts selectivity for the “essential” tryptophan residue could 
undergo electrophilic attack at a nearby zinc-coordinating cysteine residue while still being a weak 
enough electrophile to avoid unwanted side reactions by leveraging the proximity of the cysteine 
and tryptophan residues.  
In order to expand upon the previously studied series of gold(III) complexes of the form 
[Au(dien)(N-heterocycle)]3+, and to complete the series of isoelectronic and isostructural 
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platinum(II), palladium(II), and gold(III) complexes containing 1-methylcytosine as a ligand, the 
complex [Au(dien)(1-MeCyt)]3+ was investigated. This previously unreported complex, along 
with the analogous [Au(N-medien)(1-MeCyt)]3+ were investigated for their ability to interact with 
N-acetyltryptophan and the C-terminal zinc finger of NCp7 as models for the full protein. The 
enhancement of the π-π stacking ability of the aurated complexes over the free N-heterocycle is in 
agreement with the enhancement observed for the previously studied N-hetercyclic ligands. For 
the first time, formation of oxidized dimerized peptide was observed by mass spectrometry, 
indicating that these complexes possessed a reactivity profile distinct from the previously 
investigated complexes containing other N-heterocyclic ligands. Additionally, a vital feature of 
the substitution-inert complexes is the stabilization of the gold(III) oxidation state using the AuN4 
coordination sphere. As expected, the stabilization observed for the complex [Au(dien)(1-
MeCyt)]3+ follows the trend of ligand basicity, and the reduction potential is intermediate between 
the previously studied DMAP and 9-EtGua analogs.  
In order to further build upon the structure activity relationships of AuN4 complexes and to 
investigate the effect of additional steric hindrance on the interactions with NCp7, gold(III) 
complexes with the chelates BPMA and Me-BPMA were synthesized. These complexes were 
synthesized alongside the isostructural and isoelectronic platinum(II) complexes in order to make 
direct comparisons. The upfield 1H-NMR shifts observed metalation of the chelating are more 
pronounced in the case of the gold(III) than in the platinum(II), highlighting the increased 
electronegativity of gold(III) relative to platinum(II). Both the gold(III) and platinum(II) 
complexes possessing the MClN3 coordination sphere are capable of ejecting zinc from the zinc 
finger structural motif, but the gold(III) analogs eject the central zinc atom much more rapidly than 
the platinum(II) analogs. Finally, while the PtN4 complexes, which incorporate an N-heterocycle 
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creating a “formally substitution-inert” complex, were stable and isolable, the gold(III) analogs 
were too unstable to be isolated, likely due to the increase of steric hindrance imparted by the 
chelating ligand. In addition to the steric demands of the BPMA chelate, the electronic demands 
in going from sp3 in the case of dien to sp2/sp3 may also contribute to the instability of the AuN4 
complexes. 
In the future, it would be possible to expand the investigation of AuN4 complexes as NCp7 
inhibitors. The complexes studied in this work have not been able to match the inhibitory ability 
of the current lead organic compounds such as 4-(Hydroxymethyl)-6-phenyl-2,3-
dihydropyridazin-3-one, which act by competing with nucleic acids for binding to NCp7, similarly 
to the previously studied platinum(II) complexes. The leading platinum(II) candidate for further 
development is [Pt(dien)(xanthosine)]2+. The aurated analog of this complex has not yet been 
investigated. Therefore, in order to further study gold(III) complexes as inhibitors of NCp7, and 
to develop a complex capable of rivaling the current organic compounds in NCp7 inhibitory 
activity, the complex [Au(dien)(xanthosine)]3+ should be investigated. 
A significant portion of the current investigation into gold coordination-complexes centers 
around the incorporation of a gold-carbon bond. Organometallic gold complexes possess a 
reactivity profile distinct from the previously investigated AuClN3 and AuN4 complexes. In order 
to extend this observation to the NCp7 system, the complex [AuCl2(dampa)] and the 
triphenylphosphine analog [AuCl(dampa)(PPh3)]
1+ were investigated. Upon interaction with N-
acetylcysteine and glutathione, these complexes showed the ability undergo a C-S transfer, 
resulting in cysteine arylation. This interaction draws parallels to the mechanism by which N-ada 
repairs methylated DNA by transferring the methyl group onto a zinc-bound cysteine residue in a 
zinc finger motif. The triphenylphosphine complex displays “transphobia” and was synthesized 
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with the intent of blocking the chloride cis- to the gold-carbon bond. The ability of the 
triphenylphosphine complex to undergo cysteine arylation despite lacking the cis-chloride 
disproves the previously published assertion that the cis-chloride was essential for the carbon-
sulfur transfer to take place. The reactions of the complexes with the dampa chelate highlight the 
increased flexibility of the dampa chelate relative to the previously investigated benzylpyridine 
chelate, and it is possible that the reductive elimination mechanism releases the gold(I) complex 
[(PPh3)AuCl], which has been previously studied as a zinc ejector. 
Additionally, it was found using the short model peptide ACPECP that gold(III) complexes 
undergo reduction when cysteine residues are oxidized, resulting in disulfide bond formation. This 
is in contrast to gold(I) complexes, which are not reduced and likely bond so as to bridge the 
cysteine residues. This coordination motif is likely more favorable in the case of gold(I), as the 
linear geometry of the metal coordination sphere is maintained. 
This work serves to expand the knowledge of how the steric and electronic environment of the 
gold metal center affects the interactions of gold coordination complexes with NCp7. This work 
was undertaken with the goal of selectively inhibiting NCp7, and although a complex that did not 
display reactivity towards sulfur-containing biomolecules such as glutathione was not achieved, 
the information gained by the investigation of these complexes will aid future investigators to 
develop a complex that displays the desired reactivity profile. Gold(III) complexes with an 
organometallic chelate have emerged as prime candidates for development of a selective NCp7 
inhibitor. Two approaches to impart selectivity could be: substitution of the labile chloride ligands 
in order to create a substitution-inert gold coordination sphere and the incorporation of an NCp7 
recognition element. This recognition element will likely take the form of a nucleobase or N-
heterocycle, which is capable of recognizing the “essential” tryptophan residue of NCp7 through 
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a π-π stacking interaction. This interaction will bring the metal center into close proximity with 
the highly nucleophilic zinc-bound cysteine residues, which will allow interaction with a weak 
electrophile. 
In order to continue the investigation of organometallic gold(III) complexes as potential 
selective inhibitors of NCp7, a library of complexes could be developed. The bidentate 
organometallic chelating ligands dampa and bnpy offer a well-studied starting point, while 
tridentate organometallic chelating ligands such as m-xylylenediamine offer a lower number of 
labile chloride ligands which must be replaced in order to impart selectivity. The bnpy analog of 
the triphenylphosphine complex [AuCl(dampa)(PPh3)]
1+ could be investigated to determine if 
cysteine arylation is possible at the trans position in a complex with the less flexible, more 
sterically hindered bnpy chelate. Additionally, the use of other trialkylphosphine groups could be 
used to build a library of complexes with the same organometallic chelates, but different steric and 
electronic environments. Ideally, through careful selection of a combination of a tryptophan 
recognition element and a steric and electronic environment around the metal center, a selective 
inhibitor of NCp7 can be developed. 
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Appendix: Recovery of Platinum and Gold from 
Laboratory Waste 
Introduction 
The high cost of platinum makes the recovery of platinum from residual laboratory waste a 
worthwhile endeavor. 
Experimental 
Platinum Recovery 
Platinum was recovered from residual laboratory waste in the form of K2[PtCl4] by methods 
adapted from the previously published method1.  
Liquid platinum waste was adjusted to a pH of 14 using solid sodium hydroxide. The basic 
solution was heated to evaporate the solvent. The solid residue was transferred to a porcelain 
dish, and any solid platinum waste was added. The combined solids were heated with a Meker 
burner until the color became black/grey and no smoke was observed. During heating, the solid 
was stirred in order to ensure even burning. In order to remove any residual salts, the solid/ashe 
mixture was washed with water until the filtrate was colorless and clear. The remaining solid was 
suspended in aqua regia (30 mL/1 g solid), and gently heated. The solution was filtered, and this 
process was repeated two additional times (for a total of three extractions). Potassium chloride (1 
g/1 g ash) was added to the combined aqua regia filtrate. The volume of the solution was reduced 
to 1/3 of the original volume by gently heating the solution. The solution was cooled to induce 
the crystallization of a yellow solid (K2[PtCl6]). The yellow solid was collected by filtration, 
washed with cold water, and dried. 
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The recovered K2[PtCl6] was suspended in water (10 mL/g). A solution of hydrazine 
dihydrochloride (0.1 g/mL) was added dropwise at 60°C until the solution changed from yellow 
to red. Once the solution was red, addition was stopped and the temperature was increased to 
85°C for 30 minutes. The solution as cooled to room temperature, and any remaining K2[PtCl6] 
was removed by filtration. The red filtrate was evaporated under reduced pressure, yielding 
K2[PtCl4] as a red solid. 
K2[PtCl4] was recrystallized  by dissolving the solid in a minimal amount of hot water, 
removing any residual K2[PtCl6] by filtration while the solution was hot, and evaporating the 
solvent under reduced pressure. 
Gold Recovery 
Gold recovery was attempted by evaporating liquid gold waste to dryness. The solid was 
dissolved in aqua regia, and the solution was heated to 70 °C for two hours. The solution was 
filtered, and the filtrate was concentrated to 1/3 original volume. The solution was extracted with 
butyl diglyme. 5 wt% oxalic acid was added, and the solution was heated to 75 °C for two hours. 
The resulting gold(0) was collected by filtration. 
Results 
40 g of K2[PtCl4] was recovered. 1.5 g of gold(0) was recovered. 
References 
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